{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:27:14Z","timestamp":1792042034009,"version":"4.4.0"},"reference-count":390,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T00:00:00Z","timestamp":1777075200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":46,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02655-0","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T12:45:14Z","timestamp":1777121114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies"],"prefix":"10.1186","volume":"25","author":[{"given":"Valentin P.","family":"Shichkin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahsen","family":"Morva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay K.","family":"Ulaganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuray","family":"Erin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Nativi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona Kranjc","family":"Brezar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sweta","family":"Rani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,25]]},"reference":[{"issue":"1","key":"2655_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s13045-025-01660-y","volume":"18","author":"T Li","year":"2025","unstructured":"Li T, Zhang H, Lian M, He Q, Lv M, Zhai L, et al. Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021. J Hematol Oncol. 2025;18(1):5.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2655_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12943-024-01990-4","volume":"23","author":"M Kundu","year":"2024","unstructured":"Kundu M, Butti R, Panda VK, Malhotra D, Das S, Mitra T, et al. Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer. Mol Cancer. 2024;23(1):92.","journal-title":"Mol Cancer"},{"issue":"5","key":"2655_CR3","doi-asserted-by":"publisher","first-page":"394","DOI":"10.18632\/oncotarget.27877","volume":"12","author":"TA O\u2019Meara","year":"2021","unstructured":"O\u2019Meara TA, Tolaney SM. Tumor mutational burden as a predictor of immunotherapy response in breast cancer. Oncotarget. 2021;12(5):394\u2013400.","journal-title":"Oncotarget"},{"key":"2655_CR4","doi-asserted-by":"publisher","first-page":"1385571","DOI":"10.3389\/fimmu.2024.1385571","volume":"15","author":"Z Niu","year":"2024","unstructured":"Niu Z, Wu J, Zhao Q, Zhang J, Zhang P, Yang Y. CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies. Front Immunol. 2024;15:1385571.","journal-title":"Front Immunol"},{"issue":"1","key":"2655_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41523-023-00508-3","volume":"9","author":"V Debien","year":"2023","unstructured":"Debien V, De Caluw\u00e9 A, Wang X, Piccart-Gebhart M, Tuohy VK, Romano E, et al. Immunotherapy in breast cancer: an overview of current strategies and perspectives. NPJ Breast Cancer. 2023;9(1):7.","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"2655_CR6","doi-asserted-by":"publisher","first-page":"768","DOI":"10.20517\/cdr.2023.58","volume":"6","author":"RS Wong","year":"2023","unstructured":"Wong RS, Ong RJ, Lim JS. Immune checkpoint inhibitors in breast cancer: development, mechanisms of resistance and potential management strategies. Cancer Drug Resist. 2023;6(4):768\u201387.","journal-title":"Cancer Drug Resist"},{"issue":"4","key":"2655_CR7","doi-asserted-by":"publisher","first-page":"344","DOI":"10.3390\/vaccines13040344","volume":"13","author":"M Palma","year":"2025","unstructured":"Palma M. Advancing Breast Cancer Treatment: The Role of Immunotherapy and Cancer Vaccines in Overcoming Therapeutic Challenges. Vaccines. 2025;13(4):344.","journal-title":"Vaccines"},{"issue":"2","key":"2655_CR8","first-page":"47","volume":"1","author":"S Chaudhuri","year":"2021","unstructured":"Chaudhuri S, Thomas S, Munster P. Immunotherapy in breast cancer: A clinician\u2019s perspective. J Natl Cancer Cent. 2021;1(2):47\u201357.","journal-title":"J Natl Cancer Cent"},{"issue":"6","key":"2655_CR9","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","volume":"11","author":"TA Yap","year":"2021","unstructured":"Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of Immunotherapy Combination Strategies in Cancer. Cancer Discov. 2021;11(6):1368\u201397.","journal-title":"Cancer Discov"},{"issue":"22","key":"2655_CR10","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Cortes","year":"2018","unstructured":"Cortes P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. IMpassion130 Trial Investigators. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):2108\u201321.","journal-title":"N Engl J Med"},{"key":"2655_CR11","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"C Perou","year":"2000","unstructured":"Perou C, S\u00f8rlie T, Eisen M, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747\u201352.","journal-title":"Nature"},{"issue":"19","key":"2655_CR12","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.3390\/cancers16193250","volume":"16","author":"S Sriramulu","year":"2024","unstructured":"Sriramulu S, Thoidingjam S, Speers C, Nyati S. Present and Future of Immunotherapy for Triple-Negative Breast Cancer. Cancers (Basel). 2024;16(19):3250.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2655_CR13","doi-asserted-by":"publisher","first-page":"763","DOI":"10.3390\/biomedicines12040763","volume":"12","author":"A Ciarka","year":"2024","unstructured":"Ciarka A, Pi\u0105tek M, P\u0119ksa R, Kunc M, Senkus E. Tumor-Infiltrating Lymphocytes (TILs) in Breast Cancer: Prognostic and Predictive Significance across Molecular Subtypes. Biomedicines. 2024;12(4):763.","journal-title":"Biomedicines"},{"key":"2655_CR14","doi-asserted-by":"publisher","first-page":"105866","DOI":"10.1016\/j.humpath.2025.105866","volume":"162","author":"BS Finkelman","year":"2025","unstructured":"Finkelman BS, Zhang H, Hicks DG, Rimm DL, Turner BM. Tumor infiltrating lymphocytes in breast cancer: A narrative review with focus on analytic validity, clinical validity, and clinical utility. Hum Pathol. 2025;162:105866.","journal-title":"Hum Pathol"},{"key":"2655_CR15","doi-asserted-by":"crossref","unstructured":"Schlam I, Loi S, Salgado R, Swain SM. Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges. ESMO Open. 2025;10(2):104120.","DOI":"10.1016\/j.esmoop.2024.104120"},{"key":"2655_CR16","doi-asserted-by":"publisher","first-page":"31","DOI":"10.36255\/exon-publications-breast-cancer-subtypes","volume-title":"Breast Cancer [Internet]","author":"E Orrantia-Borunda","year":"2022","unstructured":"Orrantia-Borunda E, Anchondo-Nu\u00f1ez P, Acu\u00f1a-Aguilar LE, G\u00f3mez-Valles FO, Ram\u00edrez-Valdespino CA. Subtypes of Breast Cancer. In: Mayrovitz HN, editor. Breast Cancer [Internet]. Brisbane (AU): Exon; 2022. pp. 31\u201342. Chapter 3."},{"issue":"7","key":"2655_CR17","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.3390\/jcm13071873","volume":"13","author":"C Tommasi","year":"2024","unstructured":"Tommasi C, Air\u00f2 G, Prattic\u00f2 F, Testi I, Corian\u00f2 M, Pellegrino B, et al. Hormone Receptor-Positive\/HER2-Positive Breast Cancer: Hormone Therapy and Anti-HER2 Treatment: An Update on Treatment Strategies. J Clin Med. 2024;13(7):1873.","journal-title":"J Clin Med"},{"key":"2655_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41523-024-00704-9","volume":"10","author":"F Cardoso","year":"2024","unstructured":"Cardoso F, Hirshfield KM, Kraynyak KA, Tryfonidis K, Bardia A. Immunotherapy for hormone receptor\u2013positive HER2-negative breast cancer. NPJ Breast Cancer. 2024;10:104.","journal-title":"NPJ Breast Cancer"},{"key":"2655_CR19","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","volume":"39","author":"F Garrido","year":"2016","unstructured":"Garrido F, Aptsiauri N, Doorduijn EM, Garcia Lora AM, van Hall T. The urgent need to recover MHC class I in cancers for effective immunotherapy. Curr Opin Immunol. 2016;39:44\u201351.","journal-title":"Curr Opin Immunol"},{"key":"2655_CR20","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s12943-023-01899-4","volume":"22","author":"X Wu","year":"2023","unstructured":"Wu X, Li T, Jiang R, Yang X, Guo H, Yang R. Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects. Mol Cancer. 2023;22:194.","journal-title":"Mol Cancer"},{"key":"2655_CR21","doi-asserted-by":"publisher","first-page":"217432","DOI":"10.1016\/j.canlet.2024.217432","volume":"611","author":"S Kong","year":"2025","unstructured":"Kong S, Zhang J, Wang L, Li W, Guo H, Weng Q, et al. Mechanisms of low MHC I expression and strategies for targeting MHC I with small molecules in cancer immunotherapy. Cancer Lett. 2025;611:217432.","journal-title":"Cancer Lett"},{"issue":"13","key":"2655_CR22","doi-asserted-by":"publisher","first-page":"7346","DOI":"10.3390\/ijms25137346","volume":"25","author":"Y Wang","year":"2024","unstructured":"Wang Y, Li J, Nakahata S, Iha H. Complex Role of Regulatory T Cells (Tregs) in the Tumor Microenvironment: Their Molecular Mechanisms and Bidirectional Effects on Cancer Progression. Int J Mol Sci. 2024;25(13):7346.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2655_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10549-013-2618-7","volume":"140","author":"J Markowitz","year":"2013","unstructured":"Markowitz J, Wesolowski R, Papenfuss T, Brooks TR, Carson WE 3. Myeloid-derived suppressor cells in breast cancer. Breast Cancer Res Treat. 2013;140(1):13\u201321.","journal-title":"Breast Cancer Res Treat"},{"key":"2655_CR24","doi-asserted-by":"publisher","first-page":"1199273","DOI":"10.3389\/fimmu.2023.1199273","volume":"14","author":"H Liu","year":"2023","unstructured":"Liu H, Wang Z, Zhou Y, Yang Y. MDSCs in breast cancer: an important enabler of tumor progression and an emerging therapeutic target. Front Immunol. 2023;14:1199273.","journal-title":"Front Immunol"},{"key":"2655_CR25","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12943-024-02208-3","volume":"24","author":"S He","year":"2025","unstructured":"He S, Zheng L, Qi C. Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy. Mol Cancer. 2025;24:5.","journal-title":"Mol Cancer"},{"issue":"7","key":"2655_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/JCO.18.01010","volume":"37","author":"S Loi","year":"2019","unstructured":"Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, et al. Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers. J Clin Oncol. 2019;37(7):559\u201369.","journal-title":"J Clin Oncol"},{"issue":"3","key":"2655_CR27","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.3390\/ijms23031665","volume":"23","author":"P Ferrari","year":"2022","unstructured":"Ferrari P, Scatena C, Ghilli M, Bargagna I, Lorenzini G, Nicolini A. Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC. Int J Mol Sci. 2022;23(3):1665.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2655_CR28","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.3390\/cancers15041069","volume":"15","author":"S Slaney","year":"2023","unstructured":"Slaney S, Alonso MR, Arribas J. Immunotherapies against HER2-Positive Breast Cancer. Cancers (Basel). 2023;15(4):1069.","journal-title":"Cancers (Basel)"},{"key":"2655_CR29","doi-asserted-by":"publisher","first-page":"1097983","DOI":"10.3389\/fonc.2023.1097983","volume":"13","author":"T Yang","year":"2023","unstructured":"Yang T, Kang L, Li D, Song Y. Immunotherapy for HER-2 positive breast cancer. Front Oncol. 2023;13:1097983.","journal-title":"Front Oncol"},{"key":"2655_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","volume":"27","author":"D Mittal","year":"2014","unstructured":"Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases\u2013elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16\u201325.","journal-title":"Curr Opin Immunol"},{"issue":"5","key":"2655_CR31","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","volume":"24","author":"M Binnewies","year":"2018","unstructured":"Binnewies M, Roberts EW, Kersten K, Chan V, Fearon DF, Merad M, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24(5):541\u201350.","journal-title":"Nat Med"},{"issue":"11","key":"2655_CR32","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ccell.2024.09.010","volume":"42","author":"C Galassi","year":"2024","unstructured":"Galassi C, Chan TA, Vitale I, Galluzzi L. The hallmarks of cancer immune evasion. Cancer Cell. 2024;42(11):1825\u201363.","journal-title":"Cancer Cell"},{"issue":"1","key":"2655_CR33","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000486585","volume":"13","author":"A Steven","year":"2018","unstructured":"Steven A, Seliger B. The role of immune escape and immune cell infiltration in breast cancer. Breast Care (Basel). 2018;13(1):16\u201321.","journal-title":"Breast Care (Basel)"},{"key":"2655_CR34","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2340\/1651-226X.2024.33008","volume":"63","author":"M Otterlei Fj\u00f8rtoft","year":"2024","unstructured":"Otterlei Fj\u00f8rtoft M, Huse K, Rye IH. The tumor immune microenvironment in breast cancer progression. Acta Oncol. 2024;63:359\u201367.","journal-title":"Acta Oncol"},{"issue":"5","key":"2655_CR35","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","volume":"44","author":"AC Anderson","year":"2016","unstructured":"Anderson AC, Joller N, Kuchroo VK, Lag-3. Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. Immunity. 2016;44(5):989\u20131004.","journal-title":"Immunity"},{"issue":"11","key":"2655_CR36","doi-asserted-by":"publisher","first-page":"116463","DOI":"10.1016\/j.celrep.2025.116463","volume":"44","author":"S Li","year":"2025","unstructured":"Li S, Zhang Y, Tong H, Sun H, Liao H, Li Q, et al. Metabolic regulation of immunity in the tumor microenvironment. Cell Rep. 2025;44(11):116463.","journal-title":"Cell Rep"},{"issue":"11","key":"2655_CR37","doi-asserted-by":"publisher","first-page":"e1502128","DOI":"10.1080\/2162402X.2018.1502128","volume":"7","author":"S Burugu","year":"2018","unstructured":"Burugu S, Gao D, Leung S, Chia SK, Nielsen TO. TIM-3 expression in breast cancer. Oncoimmunology. 2018;7(11):e1502128.","journal-title":"Oncoimmunology"},{"key":"2655_CR38","doi-asserted-by":"publisher","first-page":"205031212110690","DOI":"10.1177\/20503121211069012","volume":"10","author":"B Mirlekar","year":"2022","unstructured":"Mirlekar B. Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: Its implications in cancer immunotherapy. SAGE Open Med. 2022;10:20503121211069012.","journal-title":"SAGE Open Med"},{"issue":"1","key":"2655_CR39","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","volume":"44","author":"S Imani","year":"2025","unstructured":"Imani S, Farghadani R, Roozitalab G, Maghsoudloo M, Emadi M, Moradi A, et al. Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy. J Exp Clin Cancer Res. 2025;44(1):131.","journal-title":"J Exp Clin Cancer Res"},{"key":"2655_CR40","doi-asserted-by":"publisher","first-page":"868695","DOI":"10.3389\/fphar.2022.868695","volume":"13","author":"SK Kim","year":"2022","unstructured":"Kim SK, Cho SW. The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. Front Pharmacol. 2022;13:868695.","journal-title":"Front Pharmacol"},{"key":"2655_CR41","doi-asserted-by":"publisher","first-page":"1548234","DOI":"10.3389\/fimmu.2025.1548234","volume":"16","author":"K Nair","year":"2025","unstructured":"Nair K, Somasundaram V, Kuriakose A, Krishn SR, Raben D, Salazar R, et al. Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies. Front Immunol. 2025;16:1548234.","journal-title":"Front Immunol"},{"issue":"1","key":"2655_CR42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s41467-022-35238-w","volume":"14","author":"S Tietscher","year":"2023","unstructured":"Tietscher S, Wagner J, Anzeneder T, Langwieder C, Rees M, Sobottka B, et al. A comprehensive single-cell map of T cell exhaustion-associated immune environments in human breast cancer. Nat Commun. 2023;14(1):98.","journal-title":"Nat Commun"},{"key":"2655_CR43","doi-asserted-by":"publisher","first-page":"1507283","DOI":"10.3389\/fimmu.2024.1507283","volume":"15","author":"H Xie","year":"2024","unstructured":"Xie H, Xi X, Lei T, Liu H, Xia Z. CD8\u2009+\u2009T cell exhaustion in the tumor microenvironment of breast cancer. Front Immunol. 2024;15:1507283.","journal-title":"Front Immunol"},{"issue":"4","key":"2655_CR44","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.immuni.2004.08.010","volume":"21","author":"C-T Huang","year":"2004","unstructured":"Huang C-T, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, et al. Role of LAG-3 in regulatory T cells. Immunity. 2004;21(4):503\u201313.","journal-title":"Immunity"},{"issue":"32","key":"2655_CR45","doi-asserted-by":"publisher","first-page":"13445","DOI":"10.1073\/pnas.0901944106","volume":"106","author":"DQ Tran","year":"2009","unstructured":"Tran DQ, Andersson J, Wang R, Ramsey H, Unutmaz D, Shevach EM. GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3\u2009+\u2009regulatory T cells. Proc Natl Acad Sci USA. 2009;106(32):13445\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"2655_CR46","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1091\/mbc.e11-12-1018","volume":"23","author":"R Wang","year":"2012","unstructured":"Wang R, Zhu J, Dong X, Shi M, Lu C, Springer TA. GARP regulates the bioavailability and activation of TGF\u03b2. Mol Biol Cell. 2012;23(6):1129\u201336.","journal-title":"Mol Biol Cell"},{"issue":"2","key":"2655_CR47","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.it.2025.01.001","volume":"46","author":"Y Wen","year":"2025","unstructured":"Wen Y, Xia Y, Yang X, Li H, Gao Q. CCR8: a promising therapeutic target against tumor-infiltrating regulatory T cells. Trends Immunol. 2025;46(2):153\u201365.","journal-title":"Trends Immunol"},{"key":"2655_CR48","doi-asserted-by":"publisher","first-page":"865593","DOI":"10.3389\/fimmu.2022.865593","volume":"13","author":"J Lee","year":"2022","unstructured":"Lee J, Kim D, Min B. Tissue resident foxp3\u2009+\u2009regulatory T cells: sentinels and saboteurs in health and disease. Front Immunol. 2022;13:865593.","journal-title":"Front Immunol"},{"key":"2655_CR49","doi-asserted-by":"publisher","first-page":"964442","DOI":"10.3389\/fimmu.2022.964442","volume":"13","author":"Q Tang","year":"2022","unstructured":"Tang Q, Chen Y, Li X, Long S, Shi Y, Yu Y, et al. The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front Immunol. 2022;13:964442.","journal-title":"Front Immunol"},{"issue":"1","key":"2655_CR50","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12943-024-02176-8","volume":"23","author":"M Jin","year":"2024","unstructured":"Jin M, Fang J, Peng J, Wang X, Xing P, Jia K, et al. PD-1\/PD-L1 immune checkpoint blockade in breast cancer: research insights and sensitization strategies. Mol Cancer. 2024;23(1):266.","journal-title":"Mol Cancer"},{"issue":"6","key":"2655_CR51","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/14728222.2018.1471137","volume":"22","author":"VS Nair","year":"2018","unstructured":"Nair VS, Toor SM, Ali BR, Elkord E. Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells. Expert Opin Ther Targets. 2018;22(6):547\u201357.","journal-title":"Expert Opin Ther Targets"},{"issue":"10","key":"2655_CR52","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3390\/cancers11101479","volume":"11","author":"I Zerdes","year":"2019","unstructured":"Zerdes I, Wallerius M, Sifakis EG, Wallmann T, Betts S, Bartish M, et al. STAT3 activity promotes programmed-death Ligand 1 expression and suppresses Immune responses in breast Cancer. Cancers (Basel). 2019;11(10):1479.","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2655_CR53","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/j.celrep.2017.02.011","volume":"18","author":"SJ Hogg","year":"2017","unstructured":"Hogg SJ, Vervoort SJ, Deswal S, Ott CJ, Li J, Cluse LA, et al. BET-Bromodomain inhibitors engage the host Immune System and regulate expression of the Immune checkpoint ligand PD-L1. Cell Rep. 2017;18(9):2162\u201374.","journal-title":"Cell Rep"},{"key":"2655_CR54","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.1038\/ncomms6241","volume":"5","author":"L Chen","year":"2014","unstructured":"Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn Y-H, Byers LA, et al. Metastasis is regulated via microRNA-200\/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014;5:5241.","journal-title":"Nat Commun"},{"issue":"7693","key":"2655_CR55","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544\u20138.","journal-title":"Nature"},{"key":"2655_CR56","doi-asserted-by":"publisher","first-page":"106939","DOI":"10.1016\/j.intimp.2020.106939","volume":"88","author":"L Li","year":"2020","unstructured":"Li L, Yu R, Cai T, Chen Z, Lan M, Zou T, et al. Effects of immune cells and cytokines on inflammation and immunosuppression in the tumor microenvironment. Int Immunopharmacol. 2020;88:106939.","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"2655_CR57","doi-asserted-by":"publisher","first-page":"a022277","DOI":"10.1101\/cshperspect.a022277","volume":"9","author":"J Seoane","year":"2017","unstructured":"Seoane J, Gomis RR. TGF-\u03b2 Family Signaling in Tumor Suppression and Cancer Progression. Cold Spring Harb Perspect Biol. 2017;9(12):a022277.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"1","key":"2655_CR58","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13045-021-01053-x","volume":"14","author":"B Kim","year":"2021","unstructured":"Kim B, Malek E, Choi SH, Ignatz-Hoover JJ, Driscoll JJ. Novel therapies emerging in oncology to target the TGF-\u03b2 pathway. J Hematol Oncol. 2021;14(1):55.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2655_CR59","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.bbrc.2018.05.139","volume":"502","author":"X Xu","year":"2018","unstructured":"Xu X, Zhang L, He X, Zhang P, Sun C, Xu X, et al. TGF-\u03b2 plays a vital role in triple-negative breast cancer (TNBC) drug-resistance through regulating stemness, EMT and apoptosis. Biochem Biophys Res Commun. 2018;502(1):160\u201365.","journal-title":"Biochem Biophys Res Commun"},{"issue":"14","key":"2655_CR60","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1038\/s41388-021-01711-x","volume":"40","author":"M Jalalirad","year":"2021","unstructured":"Jalalirad M, Haddad TC, Salisbury JL, Radisky D, Zhang M, Schroeder M, et al. Aurora-A kinase oncogenic signaling mediates TGF-\u03b2-induced triple-negative breast cancer plasticity and chemoresistance. Oncogene. 2021;40(14):2509\u201323.","journal-title":"Oncogene"},{"key":"2655_CR61","first-page":"9","volume":"30","author":"M Zhang","year":"2021","unstructured":"Zhang M, Zhang YY, Chen Y, Wang J, Wang Q, Lu H. TGF-\u03b2 Signaling and Resistance to Cancer Therapy. Front Cell Dev Biol. 2021;30:9.","journal-title":"Front Cell Dev Biol"},{"issue":"Suppl 4","key":"2655_CR62","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1186\/1471-2164-15-S4-S2","volume":"15","author":"ES Acuner-Ozbabacan","year":"2014","unstructured":"Acuner-Ozbabacan ES, Engin BH, Guven-Maiorov E, Kuzu G, Muratcioglu S, Baspinar A, et al. The structural network of Interleukin-10 and its implications in inflammation and cancer. BMC Genomics. 2014;15(Suppl 4):S2.","journal-title":"BMC Genomics"},{"key":"2655_CR63","doi-asserted-by":"publisher","first-page":"703","DOI":"10.2147\/CMAR.S225376","volume":"12","author":"X Song","year":"2020","unstructured":"Song X, Liu Z, Yu Z. EGFR promotes the development of triple negative breast cancer through JAK\/STAT3 signaling. Cancer Manag Res. 2020;12:703\u201317.","journal-title":"Cancer Manag Res"},{"issue":"3","key":"2655_CR64","doi-asserted-by":"publisher","first-page":"203","DOI":"10.4103\/tcmj.tcmj_162_20","volume":"33","author":"CM Chang","year":"2021","unstructured":"Chang CM, Lam HYP, Hsu HJ, Jiang SJ. Interleukin-10: A double-edged sword in breast cancer. Tzu Chi Med J. 2021;33(3):203\u201311.","journal-title":"Tzu Chi Med J"},{"issue":"2","key":"2655_CR65","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s12032-014-0352-6","volume":"32","author":"C Yang","year":"2015","unstructured":"Yang C, He L, He P, Liu Y, Wang W, He Y, et al. Increased drug resistance in breast cancer by tumor-associated macrophages through IL-10\/STAT3\/bcl-2 signaling pathway. Med Oncol. 2015;32(2):352.","journal-title":"Med Oncol"},{"issue":"11","key":"2655_CR66","doi-asserted-by":"publisher","first-page":"11533","DOI":"10.1007\/s13277-014-2249-6","volume":"35","author":"Y Li","year":"2014","unstructured":"Li Y, Gao P, Yang J, Yu H, Zhu Y, Si W. Relationship between IL-10 expression and prognosis in patients with primary breast cancer. Tumour Biol. 2014;35(11):11533\u201340.","journal-title":"Tumour Biol"},{"issue":"4","key":"2655_CR67","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3390\/biomedicines13040990","volume":"13","author":"H Sabit","year":"2025","unstructured":"Sabit H, Abouelnour S, Hassen BM, Magdy S, Yasser A, Soliman Wadan A, et al. Anticancer Potential of Prebiotics: Targeting Estrogen Receptors and PI3K\/AKT\/mTOR in Breast Cancer. Biomedicines. 2025;13(4):990.","journal-title":"Biomedicines"},{"issue":"2","key":"2655_CR68","doi-asserted-by":"publisher","first-page":"190","DOI":"10.5114\/ceji.2018.76273","volume":"44","author":"K Kwa\u015bniak","year":"2019","unstructured":"Kwa\u015bniak K, Czarnik-Kwa\u015bniak J, Maziarz A, Aebisher D, Zieli\u0144ska K, Karczmarek-Borowska B, et al. Scientific reports concerning the impact of interleukin 4, interleukin 10 and transforming growth factor \u03b2 on cancer cells. Cent Eur J Immunol. 2019;44(2):190\u2013200.","journal-title":"Cent Eur J Immunol"},{"key":"2655_CR69","doi-asserted-by":"publisher","first-page":"456","DOI":"10.3389\/fonc.2019.00456","volume":"9","author":"AC Little","year":"2019","unstructured":"Little AC, Pathanjeli P, Wu Z, Bao L, Goo LE, Yates JA, et al. IL-4\/IL-13 Stimulated Macrophages Enhance Breast Cancer Invasion Via Rho-GTPase Regulation of Synergistic VEGF\/CCL-18 Signaling. Front Oncol. 2019;9:456.","journal-title":"Front Oncol"},{"issue":"4","key":"2655_CR70","first-page":"193","volume":"10","author":"Z Faghih","year":"2013","unstructured":"Faghih Z, Rezaeifard S, Safaei A, Ghaderi A, Erfani N. IL-17 and IL-4 producing CD8\u2009+\u2009T cells in tumor draining lymph nodes of breast cancer patients: positive association with tumor progression. Iran J Immunol. 2013;10(4):193\u2013204.","journal-title":"Iran J Immunol"},{"issue":"12","key":"2655_CR71","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1158\/0008-5472.CAN-16-3126","volume":"77","author":"M Gaggianesi","year":"2017","unstructured":"Gaggianesi M, Turdo A, Chinnici A, Lipari E, Apuzzo T, Benfante A, et al. IL4 Primes the Dynamics of Breast Cancer Progression via DUSP4 Inhibition. Cancer Res. 2017;77(12):3268\u201379.","journal-title":"Cancer Res"},{"issue":"5","key":"2655_CR72","first-page":"2255","volume":"8","author":"G Chen","year":"2016","unstructured":"Chen G, Liang Y, Guan X, Chen H, Liu Q, Lin B, et al. Circulating low IL-23: IL-35 cytokine ratio promotes progression associated with poor prognosis in breast cancer. Am J Transl Res. 2016;8(5):2255\u201364.","journal-title":"Am J Transl Res"},{"key":"2655_CR73","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.cyto.2016.09.012","volume":"89","author":"Z Zhao","year":"2017","unstructured":"Zhao Z, Chen X, Hao S, Jia R, Wang N, Chen S, et al. Increased interleukin-35 expression in tumor-infiltrating lymphocytes correlates with poor prognosis in patients with breast cancer. Cytokine. 2017;89:76\u201381.","journal-title":"Cytokine"},{"issue":"12","key":"2655_CR74","doi-asserted-by":"publisher","first-page":"1488","DOI":"10.1093\/carcin\/bgy136","volume":"39","author":"S Hao","year":"2018","unstructured":"Hao S, Chen X, Wang F, Shao Q, Liu J, Zhao H, et al. Breast cancer cell-derived IL-35 promotes tumor progression via induction of IL-35-producing induced regulatory T cells. Carcinogenesis. 2018;39(12):1488\u201396.","journal-title":"Carcinogenesis"},{"issue":"12","key":"2655_CR75","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1111\/febs.16359","volume":"289","author":"J Liu","year":"2022","unstructured":"Liu J, Dong N, Li N, Zhao H, Li Y, Mao H, et al. IL-35 enhances angiogenic effects of small extracellular vesicles in breast cancer. FEBS J. 2022;289(12):3489\u2013504.","journal-title":"FEBS J"},{"issue":"2","key":"2655_CR76","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.immuni.2023.01.004","volume":"56","author":"S Dikiy","year":"2023","unstructured":"Dikiy S, Rudensky AY. Principles of regulatory T cell function. Immunity. 2023;56(2):240\u201355.","journal-title":"Immunity"},{"issue":"1","key":"2655_CR77","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41392-023-01471-y","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. Signal Transduct Target Therapy. 2023;8(1):235.","journal-title":"Signal Transduct Target Therapy"},{"issue":"18","key":"2655_CR78","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.3390\/cells13181526","volume":"13","author":"H Zhang","year":"2024","unstructured":"Zhang H, Felthaus O, Eigenberger A, Klein S, Prantl L. Treg Cell Therapeutic Strategies for Breast Cancer: Holistic to Local Aspects. Cells. 2024;13(18):1526.","journal-title":"Cells"},{"issue":"4","key":"2655_CR79","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/cells14040283","volume":"14","author":"B Arneth","year":"2025","unstructured":"Arneth B. Molecular Mechanisms of Immune Regulation: A Review. Cells. 2025;14(4):283.","journal-title":"Cells"},{"issue":"1","key":"2655_CR80","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1186\/s12943-024-02156-y","volume":"23","author":"A Zhang","year":"2024","unstructured":"Zhang A, Fan T, Liu Y, Yu G, Li C, Jiang Z. Regulatory T cells in immune checkpoint blockade antitumor therapy. Mol Cancer. 2024;23(1):251.","journal-title":"Mol Cancer"},{"issue":"3","key":"2655_CR81","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.ccell.2020.07.004","volume":"38","author":"M de Miguel","year":"2020","unstructured":"de Miguel M, Calvo E. Clinical challenges of Immune Checkpoint inhibitors. Cancer Cell. 2020;38(3):326\u201333.","journal-title":"Cancer Cell"},{"key":"2655_CR82","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. Front Oncol. 2018;8:86.","journal-title":"Front Oncol"},{"key":"2655_CR83","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"D Gabrilovich","year":"2009","unstructured":"Gabrilovich D, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162\u201374.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"2655_CR84","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/2326-6066.CIR-16-0297","volume":"5","author":"DI Gabrilovich","year":"2017","unstructured":"Gabrilovich DI. Myeloid-Derived Suppressor Cells. Cancer Immunol Res. 2017;5(1):3\u20138.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"2655_CR85","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1186\/s12943-022-01657-y","volume":"21","author":"Y Wu","year":"2022","unstructured":"Wu Y, Yi M, Niu M, Mei Q, Wu K. Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy. Mol Cancer. 2022;21(1):184.","journal-title":"Mol Cancer"},{"key":"2655_CR86","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40364-023-00475-8","volume":"11","author":"S Wang","year":"2023","unstructured":"Wang S, Zhao X, Wu S, Cui D, Xu Z. Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies. Biomark Res. 2023;11:34.","journal-title":"Biomark Res"},{"key":"2655_CR87","doi-asserted-by":"publisher","first-page":"844866","DOI":"10.3389\/fimmu.2022.844866","volume":"13","author":"BC Taylor","year":"2022","unstructured":"Taylor BC, Balko JM. Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response. Front Immunol. 2022;13:844866.","journal-title":"Front Immunol"},{"issue":"1","key":"2655_CR88","doi-asserted-by":"publisher","first-page":"e144344","DOI":"10.1172\/JCI144344","volume":"131","author":"D Dersh","year":"2021","unstructured":"Dersh D, Yewdell JW. Immune MAL2-practice: breast cancer immunoevasion via MHC class I degradation. J Clin Invest. 2021;131(1):e144344.","journal-title":"J Clin Invest"},{"issue":"5","key":"2655_CR89","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/PAS.0000000000001653","volume":"45","author":"AC Dusenbery","year":"2021","unstructured":"Dusenbery AC, Maniaci JL, Hillerson ND, Dill EA, Bullock TN, Mills AM. MHC Class I Loss in Triple-negative Breast Cancer: A Potential Barrier to PD-1\/PD-L1 Checkpoint Inhibitors. Am J Surg Pathol. 2021;45(5):701\u201307.","journal-title":"Am J Surg Pathol"},{"issue":"12","key":"2655_CR90","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nri3339","volume":"12","author":"KS Kobayashi","year":"2012","unstructured":"Kobayashi KS, van den Elsen PJ. NLRC5: a key regulator of MHC class I-dependent immune responses. Nat Rev Immunol. 2012;12(12):813\u201320.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2655_CR91","doi-asserted-by":"publisher","first-page":"e1005088","DOI":"10.1371\/journal.pgen.1005088","volume":"11","author":"K Ludigs","year":"2015","unstructured":"Ludigs K, Segu\u00edn-Est\u00e9vez Q, Lemeille S, Ferrero I, Rota G, Chelbi S, et al. NLRC5 exclusively transactivates MHC class I and related genes through a distinctive SXY module. PLoS Genet. 2015;11(3):e1005088.","journal-title":"PLoS Genet"},{"key":"2655_CR92","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3389\/fimmu.2017.00150","volume":"8","author":"S Benko","year":"2017","unstructured":"Benko S, Kov\u00e1cs EG, Hezel F, Kufer TA. NLRC5 Functions beyond MHC I Regulation - What Do We Know So Far? Front. Immunol. 2017;8:150. https:\/\/doi.org\/10.3389\/fimmu.2017.00150.","journal-title":"Immunol"},{"issue":"1","key":"2655_CR93","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41467-017-02630-w","volume":"9","author":"N Luo","year":"2018","unstructured":"Luo N, Nixon MJ, Gonzalez-Ericsson PI, Sanchez V, Opalenik SR, Li H, et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in Breast cancer. Nat Commun. 2018;9(1):248.","journal-title":"Nat Commun"},{"issue":"8","key":"2655_CR94","doi-asserted-by":"publisher","first-page":"e153167","DOI":"10.1172\/JCI153167","volume":"132","author":"J Ren","year":"2022","unstructured":"Ren J, Li N, Pei S, Lian Y, Li L, Peng Y, et al. Histone methyltransferase WHSC1 loss dampens MHC-I antigen presentation pathway to impair IFN-gamma-stimulated antitumor immunity. J Clin Invest. 2022;132(8):e153167.","journal-title":"J Clin Invest"},{"issue":"18","key":"2655_CR95","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1016\/j.cell.2023.07.016","volume":"186","author":"X Chen","year":"2023","unstructured":"Chen X, Lu Q, Zhou H, Liu J, Nadorp B, Lasry A, et al. A membrane-associated MHC-I inhibitory axis for cancer immune evasion. Cell. 2023;186(18):3903\u2013e2021.","journal-title":"Cell"},{"issue":"10","key":"2655_CR96","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00251-018-1074-2","volume":"70","author":"MA Garrido","year":"2018","unstructured":"Garrido MA, Rodriguez T, Zinchenko S, Maleno I, Ruiz-Cabello F, Concha \u00c1, et al. HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15. Immunogenetics. 2018;70(10):647\u201359.","journal-title":"Immunogenetics"},{"key":"2655_CR97","doi-asserted-by":"publisher","first-page":"636568","DOI":"10.3389\/fimmu.2021.636568","volume":"12","author":"K Dhatchinamoorthy","year":"2021","unstructured":"Dhatchinamoorthy K, Colbert JD, Rock KL. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation. Front Immunol. 2021;12:636568.","journal-title":"Front Immunol"},{"key":"2655_CR98","doi-asserted-by":"publisher","first-page":"100715","DOI":"10.1016\/j.drup.2020.100715","volume":"53","author":"N Erin","year":"2020","unstructured":"Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020;53:100715.","journal-title":"Drug Resist Updat"},{"issue":"7","key":"2655_CR99","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1038\/s12276-023-01013-0","volume":"55","author":"D Yang","year":"2023","unstructured":"Yang D, Liu J, Qian H, Zhuang Q. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp Mol Med. 2023;55(7):1322\u201332.","journal-title":"Exp Mol Med"},{"issue":"1","key":"2655_CR100","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13046-020-01611-0","volume":"39","author":"GJ Yoshida","year":"2020","unstructured":"Yoshida GJ. Regulation of heterogeneous cancer-associated fibroblasts: the molecular pathology of activated signaling pathways. J Exp Clin Cancer Res. 2020;39(1):112.","journal-title":"J Exp Clin Cancer Res"},{"issue":"8","key":"2655_CR101","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.3390\/cancers14082005","volume":"14","author":"A Nagel","year":"2022","unstructured":"Nagel A, Popeda M, Muchlinska A, Sadej R, Szade J, Zielinski J, et al. ERalpha36-High Cancer-Associated Fibroblasts as an Unfavorable Factor in Triple-Negative Breast Cancer. Cancers (Basel). 2022;14(8):2005.","journal-title":"Cancers (Basel)"},{"key":"2655_CR102","doi-asserted-by":"publisher","first-page":"1568865","DOI":"10.3389\/fmolb.2025.1568865","volume":"12","author":"MR Brogna","year":"2025","unstructured":"Brogna MR, Varone V, DelSesto M, Ferrara G. The role of CAFs in therapeutic resistance in triple negative breast cancer: an emerging challenge. Front Mol Biosci. 2025;12:1568865.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"2655_CR103","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1186\/s12967-025-06744-4","volume":"23","author":"Y Li","year":"2025","unstructured":"Li Y, Wang L, Ma W, Wu J, Wu Q, Sun C. Paracrine signaling in cancer-associated fibroblasts: central regulators of the tumor immune microenvironment. J Transl Med. 2025;23(1):697.","journal-title":"J Transl Med"},{"issue":"1","key":"2655_CR104","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s12943-021-01428-1","volume":"20","author":"X Mao","year":"2021","unstructured":"Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20(1):131.","journal-title":"Mol Cancer"},{"issue":"1","key":"2655_CR105","doi-asserted-by":"publisher","first-page":"8171","DOI":"10.1038\/s41467-025-63659-w","volume":"16","author":"X Wang","year":"2025","unstructured":"Wang X, Li J, Song D, Wu Y, Liu J, Yi Z, et al. AEBP1 drives fibroblast-mediated T cell dysfunction in tumors. Nat Commun. 2025;16(1):8171.","journal-title":"Nat Commun"},{"issue":"2","key":"2655_CR106","doi-asserted-by":"publisher","first-page":"e1189","DOI":"10.1002\/ctm2.1189","volume":"13","author":"S Zheng","year":"2023","unstructured":"Zheng S, Liang JY, Tang Y, Xie J, Zou Y, Yang A, et al. Dissecting the role of cancer-associated fibroblast-derived biglycan as a potential therapeutic target in immunotherapy resistance: A tumor bulk and single-cell transcriptomic study. Clin Transl Med. 2023;13(2):e1189.","journal-title":"Clin Transl Med"},{"issue":"7","key":"2655_CR107","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1158\/1078-0432.CCR-18-1955","volume":"25","author":"V Bernard","year":"2019","unstructured":"Bernard V, Semaan A, Huang J, San Lucas FA, Mulu FC, Stephens BM, et al. Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression. Clin Cancer Res. 2019;25(7):2194\u2013205.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"2655_CR108","doi-asserted-by":"publisher","first-page":"e146987","DOI":"10.1172\/JCI146987","volume":"131","author":"S Bhattacharjee","year":"2021","unstructured":"Bhattacharjee S, Hamberger F, Ravichandra A, Miller M, Nair A, Affo S, et al. Tumor restriction by type I collagen opposes tumor-promoting effects of cancer-associated fibroblasts. J Clin Invest. 2021;131(11):e146987.","journal-title":"J Clin Invest"},{"issue":"8","key":"2655_CR109","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1158\/2159-8290.CD-19-0094","volume":"9","author":"E Elyada","year":"2019","unstructured":"Elyada E, Bolisetty M, Laise P, Flynn WF, Courtois ET, Burkhart RA, et al. Cross-Species Single-Cell Analysis of Pancreatic Ductal Adenocarcinoma Reveals Antigen-Presenting Cancer-Associated Fibroblasts. Cancer Discov. 2019;9(8):1102\u201323.","journal-title":"Cancer Discov"},{"issue":"3","key":"2655_CR110","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","volume":"33","author":"A Costa","year":"2018","unstructured":"Costa A, Kieffer Y, Scholer-Dahirel A, Pelon F, Bourachot B, Cardon M, et al. Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. Cancer Cell. 2018;33(3):463\u201379. e10.","journal-title":"Cancer Cell"},{"issue":"1","key":"2655_CR111","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1038\/s41467-022-29366-6","volume":"13","author":"J Qi","year":"2022","unstructured":"Qi J, Sun H, Zhang Y, Wang Z, Xun Z, Li Z, et al. Single-cell and spatial analysis reveal interaction of FAP(+) fibroblasts and SPP1(+) macrophages in colorectal cancer. Nat Commun. 2022;13(1):1742.","journal-title":"Nat Commun"},{"issue":"1","key":"2655_CR112","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1007\/s00018-025-06056-2","volume":"83","author":"Q Ma","year":"2026","unstructured":"Ma Q, Wang J, Jiang Q. CA9\u2009+\u2009cancer-associated fibroblasts cooperate with SPP1\u2009+\u2009tumor-associated macrophages driving immune resistance in triple-negative breast cancer. Cell Mol Life Sci. 2026;83(1):54.","journal-title":"Cell Mol Life Sci"},{"issue":"18","key":"2655_CR113","doi-asserted-by":"publisher","first-page":"3291","DOI":"10.1158\/0008-5472.CAN-22-1427","volume":"82","author":"E Timperi","year":"2022","unstructured":"Timperi E, Gueguen P, Molgora M, Magagna I, Kieffer Y, Lopez-Lastra S, et al. Lipid-Associated Macrophages Are Induced by Cancer-Associated Fibroblasts and Mediate Immune Suppression in Breast Cancer. Cancer Res. 2022;82(18):3291\u2013306.","journal-title":"Cancer Res"},{"issue":"1","key":"2655_CR114","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10555-025-10241-x","volume":"44","author":"A Sattler","year":"2025","unstructured":"Sattler A, Korzun T, Gupta K, Diba P, Kyprianou N, Eksi SE. Sympathetic nerve signaling rewires the tumor microenvironment: a shift in microenvironmental-ity. Cancer Metastasis Rev. 2025;44(1):25.","journal-title":"Cancer Metastasis Rev"},{"key":"2655_CR115","doi-asserted-by":"publisher","first-page":"14824","DOI":"10.1038\/s41598-020-71670-y","volume":"10","author":"GA McCallum","year":"2020","unstructured":"McCallum GA, Shiralkar J, Suciu D, Covarrubias G, Yu JS, Karathanasis E, et al. Chronic neural activity recorded within breast tumors. Sci Rep. 2020;10:14824.","journal-title":"Sci Rep"},{"issue":"8","key":"2655_CR116","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1038\/s41593-019-0430-3","volume":"22","author":"A Kamiya","year":"2019","unstructured":"Kamiya A, Hayama Y, Kato S, Shimomura A, Shimomura T, Irie K, et al. Genetic manipulation of autonomic nerve fiber innervation and activity and its effect on breast cancer progression. Nat Neurosci. 2019;22(8):1289\u2013305.","journal-title":"Nat Neurosci"},{"issue":"4","key":"2655_CR117","doi-asserted-by":"publisher","first-page":"109883","DOI":"10.1016\/j.celrep.2021.109883","volume":"37","author":"H Mohammadpour","year":"2021","unstructured":"Mohammadpour H, MacDonald CR, McCarthy PL, Abrams SI, Repasky EA. \u03b22-adrenergic receptor signaling regulates metabolic pathways critical to myeloid-derived suppressor cell function within the TME. Cell Rep. 2021;37(4):109883.","journal-title":"Cell Rep"},{"issue":"6","key":"2655_CR118","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1096\/fba.2021-00147","volume":"4","author":"D Li","year":"2022","unstructured":"Li D, Hu LN, Zheng SM, La T, Wei LY, Zhang XJ, et al. High nerve density in breast cancer is associated with poor patient outcome. FASEB Bioadv. 2022;4(6):391\u2013401.","journal-title":"FASEB Bioadv"},{"issue":"9","key":"2655_CR119","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.3390\/cancers14092333","volume":"14","author":"N Erin","year":"2022","unstructured":"Erin N, Shurin GV, Baraldi JH, Shurin MR. Regulation of Carcinogenesis by Sensory Neurons and Neuromediators. Cancers (Basel). 2022;14(9):2333.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"2655_CR120","doi-asserted-by":"publisher","first-page":"983","DOI":"10.3390\/biom13060983","volume":"13","author":"N Erin","year":"2023","unstructured":"Erin N, Szallasi A. Carcinogenesis and Metastasis: Focus on TRPV1-Positive Neurons and Immune Cells. Biomolecules. 2023;13(6):983.","journal-title":"Biomolecules"},{"issue":"22","key":"2655_CR121","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1007\/s00018-016-2293-z","volume":"73","author":"A Mashaghi","year":"2016","unstructured":"Mashaghi A, Marmalidou A, Tehrani M, Grace PM, Pothoulakis C, Dana R. Neuropeptide substance P and the immune response. Cell Mol Life Sci. 2016;73(22):4249\u201364.","journal-title":"Cell Mol Life Sci"},{"issue":"2","key":"2655_CR122","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s00262-019-02463-0","volume":"69","author":"N Erin","year":"2020","unstructured":"Erin N. Role of sensory neurons, neuroimmune pathways, and transient receptor potential vanilloid 1 (TRPV1) channels in a murine model of breast cancer metastasis. Cancer Immunol Immunother. 2020;69(2):307\u201314.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"2655_CR123","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s10549-021-06421-2","volume":"191","author":"N Chic","year":"2022","unstructured":"Chic N, Bras\u00f3-Maristany F, Prat A. Biomarkers of immunotherapy response in breast cancer beyond PD-L1. Breast Cancer Res Treat. 2022;191(1):39\u201349.","journal-title":"Breast Cancer Res Treat"},{"key":"2655_CR124","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.breast.2023.03.014","volume":"69","author":"L Licata","year":"2023","unstructured":"Licata L, Mariani M, Rossari F, Viale G, Notini G, Naldini MM, et al. Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer. Breast. 2023;69:330\u201341.","journal-title":"Breast"},{"issue":"12","key":"2655_CR125","doi-asserted-by":"publisher","first-page":"13538","DOI":"10.1002\/cam4.6037","volume":"12","author":"Q Song","year":"2023","unstructured":"Song Q, Zhang W, Shi D, Zhang Z, Zhao Q, Wang M, et al. Overexpression of cannabinoid receptor 2 is associated with human breast cancer proliferation, apoptosis, chemosensitivity and prognosis via the PI3K\/Akt\/mTOR signaling pathway. Cancer Med. 2023;12(12):13538\u201350.","journal-title":"Cancer Med"},{"issue":"7528","key":"2655_CR126","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563\u20137.","journal-title":"Nature"},{"issue":"1","key":"2655_CR127","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1038\/s41523-024-00679-7","volume":"10","author":"SA Im","year":"2024","unstructured":"Im SA, Cortes J, Cescon DW, Yusof MM, Iwata H, Masuda N, et al. Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC. NPJ Breast Cancer. 2024;10(1):79.","journal-title":"NPJ Breast Cancer"},{"key":"2655_CR128","doi-asserted-by":"publisher","first-page":"722","DOI":"10.3389\/fphar.2020.00722","volume":"15","author":"JY Zhang","year":"2020","unstructured":"Zhang JY, Yan YY, Li JJ, Adhikari R, Fu LW. PD-1\/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake. Front Pharmacol. 2020;15:11:722.","journal-title":"Front Pharmacol"},{"issue":"1","key":"2655_CR129","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/cancers15010321","volume":"15","author":"L Li","year":"2023","unstructured":"Li L, Zhang F, Liu Z, Fan Z. Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome. Cancers (Basel). 2023;15(1):321.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2655_CR130","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, et al. IMpassion130 Investigators. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(1):44\u201359.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2655_CR131","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im S-A, Yusof MM, Gallardo C, et al. (KEYNOTE-355 Investigators). Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022;387(3):217\u201326.","journal-title":"N Engl J Med"},{"issue":"2","key":"2655_CR132","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/cells10020223","volume":"10","author":"MV Dieci","year":"2021","unstructured":"Dieci MV, Miglietta F, Guarneri V. Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications. Cells. 2021;10(2):223.","journal-title":"Cells"},{"issue":"8","key":"2655_CR133","doi-asserted-by":"publisher","first-page":"e18498","DOI":"10.1016\/j.heliyon.2023.e18498","volume":"9","author":"Y Li","year":"2023","unstructured":"Li Y, Li Y, Yang Y, Deng Y, Ni X, Zhao B, et al. Synergistic efficacy of PI3K\u03b4 inhibitor with anti-PD-1 mAbs in immune-humanized PDX model of endocrine resistance hormone receptor-positive advanced breast cancer. Heliyon. 2023;9(8):e18498.","journal-title":"Heliyon"},{"issue":"19","key":"2655_CR134","doi-asserted-by":"publisher","first-page":"31347","DOI":"10.18632\/oncotarget.15532","volume":"8","author":"M Zhang","year":"2017","unstructured":"Zhang M, Sun H, Zhao S, Wang Y, Pu H, Wang Y, et al. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis. Oncotarget. 2017;8(19):31347\u201354.","journal-title":"Oncotarget"},{"issue":"6","key":"2655_CR135","first-page":"682","volume":"14","author":"N Medi\u0107-Miliji\u0107","year":"2024","unstructured":"Medi\u0107-Miliji\u0107 N, Jovani\u0107 I, Nedeljkovi\u0107 M, Markovi\u0107 I, Spurni\u0107 I, Milovanovi\u0107 Z, et al. Prognostic and Clinical Significance of PD-L1, EGFR and Androgen Receptor (AR) Expression in Triple-Negative Breast Cancer (TNBC) Patients. Life (Basel). 2024;14(6):682.","journal-title":"Life (Basel)"},{"issue":"2","key":"2655_CR136","doi-asserted-by":"publisher","first-page":"101420","DOI":"10.1016\/j.xcrm.2024.101420","volume":"5","author":"L Wang","year":"2024","unstructured":"Wang L, Guo W, Guo Z, Yu J, Tan J, Simons DL, et al. PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer. Cell Rep Med. 2024;5(2):101420.","journal-title":"Cell Rep Med"},{"issue":"15","key":"2655_CR137","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1080\/17568919.2024.2366146","volume":"16","author":"J Tang","year":"2024","unstructured":"Tang J, Liu H, Li J, Zhang Y, Yao S, Yang K, et al. Regulation of post-translational modification of PD-L1 and associated opportunities for novel small-molecule therapeutics. Future Med Chem. 2024;16(15):1583\u201399.","journal-title":"Future Med Chem"},{"issue":"2","key":"2655_CR138","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein RM, Lee CH, Shoushtari AN, Hellmann MD, Shen R, Janjigian YY, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(2):202\u20136.","journal-title":"Nat Genet"},{"key":"2655_CR139","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-023-01850-7","volume":"22","author":"Y Liu","year":"2023","unstructured":"Liu Y, Hu Y, Xue J, Li J, Yi J, Bu J, et al. Advances in immunotherapy for triple-negative breast cancer. Mol Cancer. 2023;22:145.","journal-title":"Mol Cancer"},{"issue":"6280","key":"2655_CR140","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351(6280):1463\u20139.","journal-title":"Science"},{"issue":"9","key":"2655_CR141","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.3390\/biomedicines13092213","volume":"13","author":"PA Shatalov","year":"2025","unstructured":"Shatalov PA, Bukaeva AA, Veselovsky EM, Traspov AA, Bagdasarova DV, Leukhina IA, et al. Neoantigen-Driven Immunotherapy in Triple-Negative Breast Cancer: Emerging Strategies and Clinical Potential. Biomedicines. 2025;13(9):2213.","journal-title":"Biomedicines"},{"key":"2655_CR142","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-025-01732-z","volume":"18","author":"S Sun","year":"2025","unstructured":"Sun S, Liu L, Zhang J, Sun L, Shu W, Yang Z, et al. The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives. J Hematol Oncol. 2025;18:84.","journal-title":"J Hematol Oncol"},{"key":"2655_CR143","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-017-0424-2","volume":"9","author":"ZR Chalmers","year":"2017","unstructured":"Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.","journal-title":"Genome Med"},{"key":"2655_CR144","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.annonc.2019.11.010","volume":"31","author":"R Barroso-Sousa","year":"2020","unstructured":"Barroso-Sousa R, Jain E, Cohen O, Kim D, Buendia-Buendia J, Winer E, et al. Prevalence and mutational determinants of high tumor mutation burden in breast cancer. Ann Oncol. 2020;31:387\u201394.","journal-title":"Ann Oncol"},{"key":"2655_CR145","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1001\/jamaoncol.2016.1061","volume":"2","author":"SE Stanton","year":"2016","unstructured":"Stanton SE, Adams S, Disis ML. Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes: A Systematic Review. JAMA Oncol. 2016;2:1354\u201360.","journal-title":"JAMA Oncol"},{"issue":"1","key":"2655_CR146","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S1470-2045(17)30904-X","volume":"19","author":"C Denkert","year":"2018","unstructured":"Denkert C, von Minckwitz G, Darb-Esfahani S, Lederer B, Heppner BI, Weber KE, et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol. 2018;19(1):40\u201350.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2655_CR147","doi-asserted-by":"publisher","first-page":"767","DOI":"10.3390\/cancers15030767","volume":"15","author":"C Valenza","year":"2023","unstructured":"Valenza C, Taurelli Salimbeni B, Santoro C, Trapani D, Antonarelli G, Curigliano G. Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment. Cancers. 2023;15(3):767.","journal-title":"Cancers"},{"issue":"2","key":"2655_CR148","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1093\/annonc\/mdu450","volume":"26","author":"R Salgado","year":"2015","unstructured":"Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, International TILs Working Group 2014, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015;26(2):259\u201371.","journal-title":"Ann Oncol"},{"issue":"7","key":"2655_CR149","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/bjs.10127","volume":"103","author":"Y Asano","year":"2016","unstructured":"Asano Y, Kashiwagi S, Goto W, Kurata K, Noda S, Takashima T, et al. Tumour-infiltrating CD8 to FOXP3 lymphocyte ratio in predicting treatment responses to neoadjuvant chemotherapy of aggressive breast cancer. Br J Surg. 2016;103(7):845\u201354.","journal-title":"Br J Surg"},{"issue":"3","key":"2655_CR150","doi-asserted-by":"publisher","first-page":"287","DOI":"10.18585\/inabj.v17i3.3680","volume":"17","author":"INWT Yasa","year":"2025","unstructured":"Yasa INWT, Sudarsa IW, Niryana IW, Sriwidyani NP, Jawi IM, Yasa IWPS, et al. CD8\u2009+\u2009and Foxp3\u2009+\u2009T Cells in Breast Cancer. Indones Biomed J. 2025;17(3):287\u201394.","journal-title":"Indones Biomed J"},{"issue":"1","key":"2655_CR151","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s13058-019-1176-2","volume":"21","author":"M Sobral-Leite","year":"2019","unstructured":"Sobral-Leite M, Salomon I, Opdam M, Kruger DT, Beelen KJ, van der Noort V, et al. Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes. Breast Cancer Res. 2019;21(1):90.","journal-title":"Breast Cancer Res"},{"issue":"4","key":"2655_CR152","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","volume":"2","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361\u201370.","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"2655_CR153","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1093\/annonc\/mdx309","volume":"28","author":"AS Hamy","year":"2017","unstructured":"Hamy AS, Pierga JY, Sabaila A, Laas E, Bonsang-Kitzis H, Laurent C, et al. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer. Ann Oncol. 2017;28(9):2233\u201340.","journal-title":"Ann Oncol"},{"issue":"7","key":"2655_CR154","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1172\/JCI67428","volume":"123","author":"C Gu-Trantien","year":"2013","unstructured":"Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, de Wind A, et al. CD4\u207a follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013;123(7):2873\u201392.","journal-title":"J Clin Invest"},{"key":"2655_CR155","first-page":"477","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74:477\u201395.","journal-title":"CA Cancer J Clin"},{"key":"2655_CR156","doi-asserted-by":"publisher","first-page":"102928","DOI":"10.1016\/j.eclinm.2024.102928","volume":"78","author":"JM Vidal","year":"2024","unstructured":"Vidal JM, Tsiknakis N, Staaf J, Bosch A, Ehinger A, Nimeus E, et al. The analytical and clinical validity of AI algorithms to score TILs in TNBC: can we use different machine learning models interchangeably? EClinicalMedicine. 2024;78:102928.","journal-title":"EClinicalMedicine"},{"key":"2655_CR157","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s43042-025-00797-2","volume":"26","author":"NB Baharun","year":"2025","unstructured":"Baharun NB, Zailani MAH, Adam A, Rajpoot NM, XU Q, Zin RRM. Artificial intelligence for tumor-infiltrating lymphocytes (TILs) assessment in breast cancer: a narrative review. Egypt J Med Hum Genet. 2025;26:165.","journal-title":"Egypt J Med Hum Genet"},{"key":"2655_CR158","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s10585-023-10257-z","volume":"41","author":"C Wang","year":"2024","unstructured":"Wang C, Chen L, Fu D, Liu W, Puri A, Kellis M, et al. Antigen presenting cells in cancer immunity and mediation of immune checkpoint blockade. Clin Exp Metastasis. 2024;41:333\u201349.","journal-title":"Clin Exp Metastasis"},{"key":"2655_CR159","doi-asserted-by":"publisher","first-page":"117858","DOI":"10.1016\/j.biopha.2025.117858","volume":"184","author":"M Sheykhhasan","year":"2025","unstructured":"Sheykhhasan M, Ahmadieh-Yazdi A, Heidari R, Chamanara M, Akbari M, Poondla N, et al. Revolutionizing cancer treatment: The power of dendritic cell-based vaccines in immunotherapy. Biomed Pharmacother. 2025;184:117858.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"2655_CR160","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41568-024-00785-5","volume":"25","author":"C Luri-Rey","year":"2025","unstructured":"Luri-Rey C, Teijeira \u00c1, Wculek SK, de Andrea C, Herrero C, Lopez-Janeiro A, et al. Cross-priming in cancer immunology and immunotherapy. Nat Rev Cancer. 2025;25(4):249\u201373.","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"2655_CR161","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1038\/s41591-025-03776-7","volume":"31","author":"SY Wu","year":"2025","unstructured":"Wu SY, Jin X, Liu Y, Wang ZY, Zuo WJ, Ma D, et al. Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial. Nat Med. 2025;31(7):2405\u201315.","journal-title":"Nat Med"},{"issue":"11","key":"2655_CR162","doi-asserted-by":"publisher","first-page":"3275","DOI":"10.3390\/cancers12113275","volume":"12","author":"E Moreno","year":"2020","unstructured":"Moreno E, Cavic M, Krivokuca A, Canela EI. The Interplay between Cancer Biology and the Endocannabinoid System-Significance for Cancer Risk, Prognosis and Response to Treatment. Cancers (Basel). 2020;12(11):3275.","journal-title":"Cancers (Basel)"},{"issue":"15","key":"2655_CR163","doi-asserted-by":"publisher","first-page":"16129","DOI":"10.1002\/cam4.6267","volume":"12","author":"M Moreno","year":"2023","unstructured":"Moreno M, Oliveira JS, Brianese RC, de Castro DG, Sanches SM, Torrezan GT, et al. Risk of metastasis in BRCA2 carriers diagnosed with triple-negative breast cancer. Cancer Med. 2023;12(15):16129\u201341.","journal-title":"Cancer Med"},{"issue":"6","key":"2655_CR164","doi-asserted-by":"publisher","first-page":"djv077","DOI":"10.1093\/jnci\/djv077","volume":"107","author":"E P\u00e9rez-G\u00f3mez","year":"2015","unstructured":"P\u00e9rez-G\u00f3mez E, Andradas C, Blasco-Benito S, Caffarel MM, Garc\u00eda-Taboada E, Villa-Morales M, et al. Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer. J Natl Cancer Inst. 2015;107(6):djv077.","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"2655_CR165","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.1073\/pnas.1815034116","volume":"116","author":"S Blasco-Benito","year":"2019","unstructured":"Blasco-Benito S, Moreno E, Seijo-Vila M, Tundidor I, Andradas C, Caffarel MM, et al. Therapeutic targeting of HER2-CB2R heteromers in HER2-positive breast cancer. Proc Natl Acad Sci U S A. 2019;116(9):3863\u201372.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17","key":"2655_CR166","doi-asserted-by":"publisher","first-page":"8657","DOI":"10.3390\/ijms26178657","volume":"26","author":"HH Yoon","year":"2025","unstructured":"Yoon HH, Grimsey NL. Cannabinoid Receptor 2 (CB2) in Macrophages: A Promising Clinical Target for Immune Disorders. Int J Mol Sci. 2025;26(17):8657.","journal-title":"Int J Mol Sci"},{"key":"2655_CR167","doi-asserted-by":"publisher","first-page":"997115","DOI":"10.3389\/fimmu.2022.997115","volume":"13","author":"A Sarsembayeva","year":"2022","unstructured":"Sarsembayeva A, Haj D, Berenguer\u2013Daiz\u00e9 C, Fontaine M, Hagege A, Gross D, et al. Cannabinoid receptor 2 modulates immune infiltration and response to anti\u2013PD\u20131 in a preclinical model of lung cancer. Front Immunol. 2022;13:997115.","journal-title":"Front Immunol"},{"key":"2655_CR168","doi-asserted-by":"publisher","first-page":"2574","DOI":"10.1038\/s41467-018-04999-8","volume":"9","author":"W Xiang","year":"2018","unstructured":"Xiang W, Shi R, Kang X, Zhang X, Chen P, Zhang L, et al. Monoacylglycerol lipase regulates cannabinoid receptor 2\u2013dependent macrophage activation and cancer progression. Nat Commun. 2018;9:2574.","journal-title":"Nat Commun"},{"issue":"2","key":"2655_CR169","doi-asserted-by":"publisher","first-page":"193","DOI":"10.31083\/j.ejgo.2021.02.5463","volume":"42","author":"L Roncati","year":"2021","unstructured":"Roncati L, Vadal\u00e0 M, Corazzari V, Palmieri B. Immunohistochemical expression of cannabinoid receptors in women\u2019s cancers: What\u2019s new? Eur J Gynaecol Oncol. 2021;42(2):193\u20135.","journal-title":"Eur J Gynaecol Oncol"},{"key":"2655_CR170","doi-asserted-by":"publisher","first-page":"960579","DOI":"10.3389\/fonc.2022.960579","volume":"12","author":"Y Liu","year":"2023","unstructured":"Liu Y, Ouyang W, Huang H, Tan Y, Zhang Z, Yu Y, et al. Identification of a tumor immune inflammation signature predicting prognosis and immune status in breast cancer. Front Oncol. 2023;12:960579.","journal-title":"Front Oncol"},{"key":"2655_CR171","doi-asserted-by":"publisher","first-page":"1522262","DOI":"10.3389\/fonc.2025.1522262","volume":"15","author":"L Jin","year":"2025","unstructured":"Jin L, Yang Z, Tang W, Yu P, Chen R, Xu Y, et al. The evolving landscape of genetic biomarkers for immunotherapy in primary and metastatic breast cancer. Front Oncol. 2025;15:1522262.","journal-title":"Front Oncol"},{"issue":"4","key":"2655_CR172","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3109\/15476910903299835","volume":"6","author":"VP Shichkin","year":"2009","unstructured":"Shichkin VP, Lon AD, Yugrinova LG, Grinevich YA, Belova OB, Berezhnaya NM, et al. TNF receptor p55 and IL-872 and IL-877 isoforms: blood and urine levels in breast cancer patients. J Immunotoxicology. 2009;6(4):235\u201342.","journal-title":"J Immunotoxicology"},{"key":"2655_CR173","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41698-025-00842-8","volume":"9","author":"R Shi","year":"2025","unstructured":"Shi R, Sun J, Zhou Z, Shi M, Wang X, Gao Z, et al. Integration of multiple machine learning approaches develops a gene mutation-based classifier for accurate immunotherapy outcomes. npj Precis Onc. 2025;9:54.","journal-title":"npj Precis Onc"},{"key":"2655_CR174","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10238-025-01892-9","volume":"26","author":"R Das","year":"2026","unstructured":"Das R, Deb S, Suresh PK. TMB as a predictive biomarker for ICI response in TNBC: current evidence and future directions for augmented anti-tumor responses. Clin Exp Med. 2026;26:25.","journal-title":"Clin Exp Med"},{"key":"2655_CR175","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1186\/s12967-025-07370-w","volume":"23","author":"Y Yang","year":"2025","unstructured":"Yang Y, Wang W. Recent progress in immune evasion mechanisms of triple-negative breast cancer. J Transl Med. 2025;23:1314.","journal-title":"J Transl Med"},{"key":"2655_CR176","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13045-024-01649-z","volume":"17","author":"NK Heater","year":"2024","unstructured":"Heater NK, Warrior S, Lu J. Current and future immunotherapy for breast cancer. J Hematol Oncol. 2024;17:131.","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2655_CR177","doi-asserted-by":"publisher","first-page":"923","DOI":"10.3390\/ph16070923","volume":"16","author":"ML Nordin","year":"2023","unstructured":"Nordin ML, Azemi AK, Nordin AH, Nabgan W, Ng PY, Yusoff K, et al. Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects. Pharmaceuticals (Basel). 2023;16(7):923.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2655_CR178","doi-asserted-by":"publisher","first-page":"114685","DOI":"10.1016\/j.biopha.2023.114685","volume":"162","author":"D Qian","year":"2023","unstructured":"Qian D, Li J, Huang M, Cui Q, Liu X, Sun K. Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy. Biomed Pharmacother. 2023;162:114685.","journal-title":"Biomed Pharmacother"},{"key":"2655_CR179","doi-asserted-by":"publisher","first-page":"216634","DOI":"10.1016\/j.canlet.2024.216634","volume":"585","author":"A Bahreyni","year":"2024","unstructured":"Bahreyni A, Mohamud Y, Luo H. Oncolytic virus-based combination therapy in breast cancer. Cancer Lett. 2024;585:216634.","journal-title":"Cancer Lett"},{"issue":"3","key":"2655_CR180","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3390\/immuno4030013","volume":"4","author":"A Younis","year":"2024","unstructured":"Younis A, Gribben J. Immune Checkpoint Inhibitors: Fundamental Mechanisms, Current Status and Future Directions. Immuno. 2024;4(3):186\u2013210.","journal-title":"Immuno"},{"key":"2655_CR181","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1073\/pnas.1921445117","volume":"117","author":"X Wang","year":"2020","unstructured":"Wang X, Yang X, Zhang C, Wang Y, Cheng T, Duan L, et al. Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. Proc Natl Acad Sci USA. 2020;117:6640\u201350.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"2655_CR182","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1080\/23808993.2020.1730694","volume":"5","author":"JA Kagihara","year":"2020","unstructured":"Kagihara JA, Andress M, Diamond JR. Nab-paclitaxel and atezolizumab for the treatment of PD-L1-positive, metastatic triple-negative breast cancer: review and future directions. Expert Rev Precis Med Drug Dev. 2020;5(2):59\u201365.","journal-title":"Expert Rev Precis Med Drug Dev"},{"key":"2655_CR183","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/cancers15010104","volume":"15","author":"X Chen","year":"2022","unstructured":"Chen X, Feng L, Huang Y, Wu Y, Xie N. Mechanisms and Strategies to Overcome PD-1\/PD-L1 Blockade Resistance in Triple-Negative Breast Cancer. Cancers. 2022;15:104.","journal-title":"Cancers"},{"issue":"21","key":"2655_CR184","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, K\u00fcmmel S, et al. KEYNOTE-522 Investigators. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. N Engl J Med. 2024;391(21):1981\u201391.","journal-title":"N Engl J Med"},{"issue":"5","key":"2655_CR185","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1001\/jamaoncol.2019.6650","volume":"6","author":"R Nanda","year":"2020","unstructured":"Nanda R, Liu MC, Yau C, Shatsky R, Pusztai L, Wallace A, et al. Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. JAMA Oncol. 2020;6(5):676\u201384.","journal-title":"JAMA Oncol"},{"key":"2655_CR186","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/s41591-024-03415-7","volume":"31","author":"F Cardoso","year":"2025","unstructured":"Cardoso F, O\u2019Shaughnessy J, Liu Z, McArthur H, Schmid P, Cortes J, et al. Pembrolizumab and chemotherapy in high-risk, early-stage, ER+\/HER2- breast cancer: a randomized phase 3 trial. Nat Med. 2025;31:442\u20138.","journal-title":"Nat Med"},{"key":"2655_CR187","doi-asserted-by":"publisher","first-page":"104873","DOI":"10.1016\/j.esmoop.2025.104873","volume":"10 Suppl 4","author":"S Loi","year":"2025","unstructured":"Loi S, Zdenkowski N, Gebski V, Li I, Wilcken N, Morris M, et al. 301MO Primary efficacy results of tremelimumab and durvalumab in combination with trastuzumab in trastuzumab resistant advanced HER2-positive breast cancer: BCT1703 DIAmOND. ESMO Open. 2025;10 Suppl 4:104873.","journal-title":"ESMO Open"},{"issue":"7","key":"2655_CR188","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1093\/jimmun\/vkaf079","volume":"214","author":"AT Stopeck","year":"2025","unstructured":"Stopeck AT, Abu-Khalaf M, Borges V, Chmielowski B, Rao R, Xie B, et al. Phase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapy. J Immunol. 2025;214(7):1529\u201338.","journal-title":"J Immunol"},{"key":"2655_CR189","doi-asserted-by":"publisher","first-page":"TPS1125","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS1125","volume":"40","author":"GT Budd","year":"2022","unstructured":"Budd GT, Johnson JM, Rhoades EE, Moore HCF, Kruse ML, Roesch EE, et al. Phase I trial of an alpha-lactalbumin vaccine in patients with moderate- to high-risk operable triple-negative breast cancer (TNBC). J Clin Oncol. 2022;40:TPS1125.","journal-title":"J Clin Oncol"},{"issue":"Suppl 12","key":"2655_CR190","first-page":"PS3","volume":"31","author":"J Wu","year":"2025","unstructured":"Wu J, Zhang J, Tong Z, Zhang Q, Wang Y, Cheng Q, et al. Interim Overall Survival of Patients with Locally Advanced or Metastatic Triple-Negative Breast Cancer treated with First Line PM8002\/BNT327 in Combination with Nab-Paclitaxel in Phase Ib\/II Study. Clin Cancer Res. 2025;31(Suppl 12):PS3\u201308.","journal-title":"Clin Cancer Res"},{"key":"2655_CR191","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1200\/JCO.2021.39.15_suppl.1023","volume":"39","author":"P Schmid","year":"2021","unstructured":"Schmid P, Im S-A, Armstrong A, Park YH, Chung W-P, Nowecki Z, et al. BEGONIA: Phase 1b\/2 study of durvalumab (D) combinations in locally advanced\/metastatic triple-negative breast cancer (TNBC)-Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). J Clin Oncol. 2021;39:1023.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2655_CR192","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1159\/000453569","volume":"11","author":"AD Hartkopf","year":"2016","unstructured":"Hartkopf AD, Taran F-A, Wallwiener M, Walter CB, Kr\u00e4mer B, Grischke E-M, et al. PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer. Breast Care (Basel). 2016;11(6):385\u201390.","journal-title":"Breast Care (Basel)"},{"issue":"1","key":"2655_CR193","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12885-025-15521-x","volume":"26","author":"A Aikelaimu","year":"2026","unstructured":"Aikelaimu A, Li W, Kaicaier M, Liu S, Zhang Y, Hou X, et al. Efficacy and safety of PD-1\/PD-L1 inhibitors plus chemotherapy in breast cancer: a systematic review and meta-analysis with focus on triple-negative subtype and immune-related adverse events. BMC Cancer. 2026;26(1):242.","journal-title":"BMC Cancer"},{"issue":"1","key":"2655_CR194","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J, Xu L, Li Y. Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol. 2023;16(1):101.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2655_CR195","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.immuni.2024.01.010","volume":"57","author":"N Joller","year":"2024","unstructured":"Joller N, Anderson AC, Kuchroo VK. LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation. Immunity. 2024;57(2):206\u201322.","journal-title":"Immunity"},{"issue":"1","key":"2655_CR196","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00280-023-04627-3","volume":"94","author":"N Yamamoto","year":"2024","unstructured":"Yamamoto N, Koyama T, Sato J, Yoshida T, Sudo K, Iwasa S, et al. Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors. Cancer Chemother Pharmacol. 2024;94(1):109\u201315.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2655_CR197","doi-asserted-by":"publisher","first-page":"200773","DOI":"10.1016\/j.omton.2024.200773","volume":"32","author":"C Lu","year":"2024","unstructured":"Lu C, Tan Y. Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party. Mol Ther Oncol. 2024;32(1):200773.","journal-title":"Mol Ther Oncol"},{"issue":"4","key":"2655_CR198","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3390\/curroncol32040230","volume":"32","author":"CC Mire\u0219tean","year":"2025","unstructured":"Mire\u0219tean CC, Iancu RI, Iancu DPT. LAG3, TIM3 and TIGIT: New Targets for Immunotherapy and Potential Associations with Radiotherapy. Curr Oncol. 2025;32(4):230.","journal-title":"Curr Oncol"},{"issue":"1","key":"2655_CR199","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s43556-025-00267-6","volume":"6","author":"Z Yan","year":"2025","unstructured":"Yan Z, Wang C, Wu J, Wang J, Ma T. TIM-3 teams up with PD-1 in cancer immunotherapy: mechanisms and perspectives. Mol Biomed. 2025;6(1):2.","journal-title":"Mol Biomed"},{"issue":"1","key":"2655_CR200","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/cancers16010124","volume":"16","author":"DF Chamorro","year":"2024","unstructured":"Chamorro DF, Somes LK, Hoyos V. Engineered Adoptive T-Cell Therapies for Breast Cancer: Current Progress, Challenges, and Potential. Cancers (Basel). 2024;16(1):124.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2655_CR201","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1093\/jleuko\/qiad144","volume":"115","author":"X Li","year":"2024","unstructured":"Li X, Zhu Y, Yi J, Deng Y, Lei B, Ren H. Adoptive cell immunotherapy for breast cancer: harnessing the power of immune cells. J Leukoc Biol. 2024;115(5):866\u201381.","journal-title":"J Leukoc Biol"},{"issue":"8","key":"2655_CR202","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3390\/biom14081035","volume":"14","author":"W Li","year":"2024","unstructured":"Li W, Wang X, Zhang X, Aziz AUR, Wang D. CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges. Biomolecules. 2024;14(8):1035.","journal-title":"Biomolecules"},{"issue":"10","key":"2655_CR203","doi-asserted-by":"publisher","first-page":"3243","DOI":"10.1007\/s00262-023-03490-8","volume":"72","author":"Z Duan","year":"2023","unstructured":"Duan Z, Li Z, Wang Z, Chen C, Luo Y. Chimeric antigen receptor macrophages activated through TLR4 or IFN-\u03b3 receptors suppress breast cancer growth by targeting VEGFR2. Cancer Immunol Immunother. 2023;72(10):3243\u201357.","journal-title":"Cancer Immunol Immunother"},{"key":"2655_CR204","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41467-024-55770-1","volume":"16","author":"S Pierini","year":"2025","unstructured":"Pierini S, Gabbasov R, Oliveira-Nunes MC, Qureshi R, Worth A, Huang S, et al. Chimeric antigen receptor macrophages (CAR-M) sensitize HER2\u2009+\u2009solid tumors to PD1 blockade in pre-clinical models. Nat Commun. 2025;16:706.","journal-title":"Nat Commun"},{"key":"2655_CR205","doi-asserted-by":"publisher","first-page":"102610","DOI":"10.1016\/j.nantod.2024.102610","volume":"61","author":"J Zhou","year":"2025","unstructured":"Zhou J, Zhou Z, Wang Z, Sun L, Li F, Tang Y, et al. Lipid nanoparticles produce chimeric antigen receptor macrophages (CAR-M) in situ for the treatment of solid tumors. Nano Today. 2025;61:102610.","journal-title":"Nano Today"},{"key":"2655_CR206","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1002\/cac2.70053","volume":"45","author":"M Wang","year":"2025","unstructured":"Wang M, Qin Z, Bian W, Shi Y. Harnessing chimeric antigen receptor macrophages against solid tumors. Cancer Commun. 2025;45:1344\u201366.","journal-title":"Cancer Commun"},{"issue":"1","key":"2655_CR207","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12935-024-03615-8","volume":"25","author":"HE Marei","year":"2025","unstructured":"Marei HE, Bedair K, Hasan A, Al-Mansoori L, Caratelli S, Sconocchia G, et al. Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer. Cancer Cell Int. 2025;25(1):3.","journal-title":"Cancer Cell Int"},{"issue":"23","key":"2655_CR208","doi-asserted-by":"publisher","first-page":"11054","DOI":"10.18632\/aging.102510","volume":"11","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhou Y, Huang KH, Li Y, Fang X, An L, et al. EGFR-specific CAR-T cells trigger cell lysis in EGFR-positive TNBC. Aging. 2019;11(23):11054\u201372.","journal-title":"Aging"},{"issue":"40","key":"2655_CR209","doi-asserted-by":"publisher","first-page":"65024","DOI":"10.18632\/oncotarget.11344","volume":"7","author":"ZH Li","year":"2016","unstructured":"Li ZH, Hu PH, Tu JH, Yu NS. Luminal B breast cancer: patterns of recurrence and clinical outcome. Oncotarget. 2016;7(40):65024\u201333.","journal-title":"Oncotarget"},{"key":"2655_CR210","doi-asserted-by":"publisher","first-page":"4795171","DOI":"10.1155\/2020\/4795171","volume":"2020","author":"Z Zhao","year":"2020","unstructured":"Zhao Z, Li Y, Liu W, Li X. Engineered IL-7 receptor enhances the therapeutic effect of AXL-CAR-T cells on triple-negative breast cancer. BioMed Res Int. 2020;2020:4795171.","journal-title":"BioMed Res Int"},{"issue":"7","key":"2655_CR211","doi-asserted-by":"publisher","first-page":"112797","DOI":"10.1016\/j.celrep.2023.112797","volume":"42","author":"Y Cui","year":"2023","unstructured":"Cui Y, Yuan T, Wang Y, Zheng D, Qin L, Li S, et al. T lymphocytes expressing the switchable chimeric Fc receptor CD64 exhibit augmented persistence and antitumor activity. Cell Rep. 2023;42(7):112797.","journal-title":"Cell Rep"},{"key":"2655_CR212","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1158\/1078-0432.CCR-17-2041","volume":"24","author":"SJ Priceman","year":"2018","unstructured":"Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, et al. Regional delivery of chimeric antigen receptor\u2013engineered T cells effectively targets HER2\u2009+\u2009breast cancer metastasis to the brain. Clin Cancer Res. 2018;24:95\u2013105.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"2655_CR213","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1158\/1078-0432.CCR-16-1860","volume":"23","author":"CY Slaney","year":"2017","unstructured":"Slaney CY, von Scheidt B, Davenport AJ, Beavis PA, Westwood JA, Mardiana S, et al. Dual-specific chimeric antigen receptor T cells and an indirect vaccine eradicate a variety of large solid tumors in an immunocompetent, self-antigen setting. Clin Cancer Res. 2017;23(10):2478\u201390.","journal-title":"Clin Cancer Res"},{"key":"2655_CR214","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1002\/ijc.32663","volume":"146","author":"S Caratelli","year":"2020","unstructured":"Caratelli S, Arriga R, Sconocchia T, Ottaviani A, Lanzilli G, Pastore D, et al. In vitro elimination of EGFR-overexpressing cancer cells by CD32A chimeric receptor T cells in combination with cetuximab or panitu mumab. Int J Cancer. 2020;146:236\u201347.","journal-title":"Int J Cancer"},{"key":"2655_CR215","doi-asserted-by":"publisher","first-page":"102868","DOI":"10.1016\/j.ctrv.2024.102868","volume":"133","author":"G Buono","year":"2025","unstructured":"Buono G, Capozzi M, Caputo R, Di Lauro V, Cianniello D, Piezzo M, et al. CAR-T cell therapy for breast cancer: Current status and future perspective. Cancer Treat Rev. 2025;133:102868.","journal-title":"Cancer Treat Rev"},{"key":"2655_CR216","doi-asserted-by":"publisher","first-page":"3846","DOI":"10.1038\/s41598-018-22252-6","volume":"8","author":"JH Cho","year":"2018","unstructured":"Cho JH, Okuma A, Al-Rubaye D, Intisar E, Junghans RP, Wong WW. Engineering Axl specific CAR and SynNotch receptor for cancer therapy. Sci Rep. 2018;8:3846.","journal-title":"Sci Rep"},{"key":"2655_CR217","doi-asserted-by":"publisher","first-page":"27764","DOI":"10.18632\/oncotarget.8526","volume":"7","author":"X Chen","year":"2016","unstructured":"Chen X, Han J, Chu J, Zhang L, Zhang J, Chen C, et al. A combinational therapy of EGFR-CAR NK cells and oncolytic herpes simplex virus 1 for breast cancer brain metastases. Oncotarget. 2016;7:27764\u201377.","journal-title":"Oncotarget"},{"key":"2655_CR218","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s12185-021-03209-4","volume":"114","author":"A Biederst\u00e4dt","year":"2021","unstructured":"Biederst\u00e4dt A, Rezvani K. Engineering the next generation of CAR-NK immunotherapies. Int J Hematol. 2021;114:554\u201371.","journal-title":"Int J Hematol"},{"key":"2655_CR219","first-page":"4455","volume":"11","author":"Y-Z Lin","year":"2021","unstructured":"Lin Y-Z, Lee C-C, Cho D-Y, Wang Y-L, Chen C-Y, Weng C-Y, et al. Suppression of breast cancer cells resistant to a pure antiestrogen with CAR-transduced natural killer cells. Am J Cancer Res. 2021;11:4455.","journal-title":"Am J Cancer Res"},{"issue":"6","key":"2655_CR220","doi-asserted-by":"publisher","first-page":"102619","DOI":"10.1016\/j.isci.2021.102619","volume":"24","author":"AL Portillo","year":"2021","unstructured":"Portillo AL, Hogg R, Poznanski SM, Rojas EA, Cashell NJ, Hammill JA, et al. Expanded human NK cells armed with CAR uncouple potent antitumor activity from off-tumor toxicity against solid tumors. iScience. 2021;24(6):102619.","journal-title":"iScience"},{"key":"2655_CR221","doi-asserted-by":"publisher","first-page":"9038","DOI":"10.3390\/ijms24109038","volume":"24","author":"MJ Raftery","year":"2023","unstructured":"Raftery MJ, Franz\u00e9n AS, Radecke C, Boulifa A, Sch\u00f6nrich G, Stintzing S, et al. Next generation CD44v6-specific CAR-NK cells effective against triple negative breast cancer. Int J Mol Sci. 2023;24:9038.","journal-title":"Int J Mol Sci"},{"key":"2655_CR222","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","volume":"16","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang G, Wan X. Challenges and new technologies in adoptive cell therapy. J Hematol Oncol. 2023;16:97.","journal-title":"J Hematol Oncol"},{"key":"2655_CR223","doi-asserted-by":"publisher","first-page":"6843","DOI":"10.3390\/ijms24076843","volume":"24","author":"W Xia","year":"2023","unstructured":"Xia W, Chen J, Hou W, Chen J, Xiong Y, Li H, et al. Engineering a HER2-CAR-NK cell secreting soluble programmed cell death protein with superior antitumor efficacy. Int J Mol Sci. 2023;24:6843.","journal-title":"Int J Mol Sci"},{"key":"2655_CR224","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s13287-022-03054-0","volume":"13","author":"R Margiana","year":"2022","unstructured":"Margiana R, Markov A, Zekiy AO, Hamza MU, Al-Dabbagh KA, Al-Zubaidi SH, et al. Clinical application of mesenchymal stem cell in regenerative medicine: a narrative review. Stem Cell Res Ther. 2022;13:366.","journal-title":"Stem Cell Res Ther"},{"key":"2655_CR225","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40364-024-00637-2","volume":"12","author":"J Lu","year":"2024","unstructured":"Lu J, Ma Y, Li Q, Xu Y, Xue Y, Xu S. CAR Macrophages: A promising novel immunotherapy for solid tumors and beyond. Biomark Res. 2024;12:86.","journal-title":"Biomark Res"},{"issue":"12","key":"2655_CR226","doi-asserted-by":"publisher","first-page":"e007705","DOI":"10.1136\/jitc-2023-007705","volume":"11","author":"SM Abdin","year":"2023","unstructured":"Abdin SM, Paasch D, Kloos A, Oliveira MC, Jang MS, Ackermann M, et al. Scalable generation of functional human iPSC-derived CAR macrophages that efficiently eradicate CD19-positive leukemia. J Immunother Cancer. 2023;11(12):e007705.","journal-title":"J Immunother Cancer"},{"key":"2655_CR227","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.stemcr.2022.12.012","volume":"18","author":"J Zhang","year":"2023","unstructured":"Zhang J, Webster S, Duffin B, Bernstein MN, Steill J, Swanson S, et al. Generation of anti-GD2 CAR macrophages from human pluripotent stem cells for cancer immunotherapies. Stem Cell Rep. 2023;18:585\u201396.","journal-title":"Stem Cell Rep"},{"key":"2655_CR228","first-page":"e00201","volume":"6","author":"S Ebrahimabadi","year":"2024","unstructured":"Ebrahimabadi S, Kaufman DS. Next-generation macrophages: Repolarizing CAR-macrophages against cancer. Blood Sci (Baltimore MD). 2024;6:e00201.","journal-title":"Blood Sci (Baltimore MD)"},{"issue":"7","key":"2655_CR229","doi-asserted-by":"publisher","first-page":"eadf3700","DOI":"10.1126\/sciadv.adf3700","volume":"9","author":"E Baulu","year":"2023","unstructured":"Baulu E, Gardet C, Chuvin N, Depil S. TCR-engineered T cell therapy in solid tumors: State of the art and perspectives. Sci Adv. 2023;9(7):eadf3700.","journal-title":"Sci Adv"},{"key":"2655_CR230","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1158\/2326-6066.CIR-22-0040","volume":"10","author":"SP Kim","year":"2022","unstructured":"Kim SP, Vale NR, Zacharakis N, Krishna S, Yu Z, Gasmi B, et al. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-Cell Receptor-Engineered T Cells Targeting CommonP53Neoantigens in Human Solid Tumors. Cancer Immunol Res. 2022;10:932\u201346.","journal-title":"Cancer Immunol Res"},{"key":"2655_CR231","doi-asserted-by":"publisher","first-page":"835762","DOI":"10.3389\/fimmu.2022.835762","volume":"13","author":"P Shafer","year":"2022","unstructured":"Shafer P, Kelly LM, Hoyos V. Cancer Therapy with TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects. Front Immunol. 2022;13:835762.","journal-title":"Front Immunol"},{"key":"2655_CR232","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13045-019-0812-8","volume":"12","author":"Q He","year":"2019","unstructured":"He Q, Jiang X, Zhou X, Weng J. Targeting Cancers through TCR-Peptide\/MHC Interactions. J Hematol Oncol. 2019;12:139.","journal-title":"J Hematol Oncol"},{"key":"2655_CR233","doi-asserted-by":"publisher","first-page":"786438","DOI":"10.3389\/fonc.2022.786438","volume":"12","author":"S Zhou","year":"2022","unstructured":"Zhou S, Liu S, Zhao L, Sun HX. A Comprehensive Survey of Genomic Mutations in Breast Cancer Reveals Recurrent Neoantigens as Potential Therapeutic Targets. Front Oncol. 2022;12:786438.","journal-title":"Front Oncol"},{"issue":"2","key":"2655_CR234","doi-asserted-by":"publisher","first-page":"195","DOI":"10.3390\/immuno3020013","volume":"3","author":"M Vasileiou","year":"2023","unstructured":"Vasileiou M, Papageorgiou S, Nguyen NP. Current Advancements and Future Perspectives of Immunotherapy in Breast Cancer Treatment. Immuno. 2023;3(2):195\u2013216.","journal-title":"Immuno"},{"key":"2655_CR235","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.4049\/jimmunol.1100681","volume":"187","author":"A-H Capietto","year":"2011","unstructured":"Capietto A-H, Martinet L, Fourni\u00e9 J-J. Stimulated \u03d2\u03b4 T Cells Increase the in Vivo Efficacy of Trastuzumab in HER-2\u2009+\u2009Breast Cancer. J Immunol. 2011;187:1031\u201338.","journal-title":"J Immunol"},{"key":"2655_CR236","doi-asserted-by":"publisher","first-page":"eaax9364","DOI":"10.1126\/scitranslmed.aax9364","volume":"11","author":"Y Wu","year":"2019","unstructured":"Wu Y, Kyle-Cezar F, Woolf RT, Naceur-Lombardelli C, Owen J, Biswas D, et al. An Innate-like V\u03b41\u2009+\u2009\u03d2\u03b4 T Cell Compartment in the Human Breast Is Associated with Remission in Triple-Negative Breast Cancer. Sci Transl Med. 2019;11:eaax9364.","journal-title":"Sci Transl Med"},{"key":"2655_CR237","doi-asserted-by":"publisher","first-page":"e003811","DOI":"10.1136\/jitc-2021-003811","volume":"10","author":"M Ishihara","year":"2022","unstructured":"Ishihara M, Kitano S, Kageyama S, Miyahara Y, Yamamoto N, Kato H, et al. NY-ESO-1-Specific Redirected T Cells with Endogenous TCR Knockdown Mediate Tumor Response and Cytokine Release Syndrome. J Immunother Cancer. 2022;10:e003811.","journal-title":"J Immunother Cancer"},{"key":"2655_CR238","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/JCO.2017.74.5463","volume":"35","author":"YC Lu","year":"2017","unstructured":"Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, et al. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. J Clin Oncol. 2017;35:3322\u20139.","journal-title":"J Clin Oncol"},{"key":"2655_CR239","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1182\/blood-2017-05-787598","volume":"131","author":"M Legut","year":"2018","unstructured":"Legut M, Dolton G, Mian AA, Ottmann OG, Sewell AK. CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells. Blood. 2018;131:311\u201322.","journal-title":"Blood"},{"key":"2655_CR240","doi-asserted-by":"publisher","first-page":"100374","DOI":"10.1016\/j.xcrm.2021.100374","volume":"2","author":"TR M\u00fcller","year":"2021","unstructured":"M\u00fcller TR, Jarosch S, Hammel M, Leube J, Grassmann S, Bernard B, et al. Targeted T cell receptor gene editing provides predictable T cell product function for immunotherapy. Cell Rep Med. 2021;2:100374.","journal-title":"Cell Rep Med"},{"key":"2655_CR241","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-05531-1","volume":"615","author":"SP Foy","year":"2023","unstructured":"Foy SP, Jacoby K, Bota DA, Hunter T, Pan Z, Stawiski E, et al. Non-viral precision T cell receptor replacement for personalized cell therapy. Nature. 2023;615:687\u201396.","journal-title":"Nature"},{"key":"2655_CR242","doi-asserted-by":"publisher","first-page":"eabg8027","DOI":"10.1126\/scitranslmed.abg8027","volume":"14","author":"E Ruggiero","year":"2022","unstructured":"Ruggiero E, Carnevale E, Prodeus A, Magnani ZI, Camisa B, Merelli I, et al. CRISPR-based gene disruption and integration of high-avidity, WT1-specific T cell receptors improve antitumor T cell function. Sci Transl Med. 2022;14:eabg8027.","journal-title":"Sci Transl Med"},{"key":"2655_CR243","doi-asserted-by":"publisher","first-page":"e003486","DOI":"10.1136\/jitc-2021-003486","volume":"10","author":"E Donnadieu","year":"2022","unstructured":"Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, et al. Time to evolve: predicting engineered T cell-associated toxicity with next-generation models. J Immunother Cancer. 2022;10:e003486.","journal-title":"J Immunother Cancer"},{"key":"2655_CR244","doi-asserted-by":"publisher","first-page":"e003487","DOI":"10.1136\/jitc-2021-003487","volume":"10","author":"S Guedan","year":"2022","unstructured":"Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, et al. Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside? J Immunother Cancer. 2022;10:e003487.","journal-title":"J Immunother Cancer"},{"key":"2655_CR245","doi-asserted-by":"publisher","first-page":"780399","DOI":"10.3389\/fimmu.2021.780399","volume":"12","author":"MA Savanur","year":"2021","unstructured":"Savanur MA, Weinstein-Marom H, Gross G. Implementing Logic Gates for Safer Immunotherapy of Cancer. Front Immunol. 2021;12:780399.","journal-title":"Front Immunol"},{"key":"2655_CR246","doi-asserted-by":"publisher","first-page":"826747","DOI":"10.3389\/fimmu.2022.826747","volume":"13","author":"D Manry","year":"2022","unstructured":"Manry D, Bolanos K, DiAndreth B, Mock JY, Kamb A. Robust In Vitro Pharmacology of Tmod, a Synthetic Dual-Signal Integrator for Cancer Cell Therapy. Front Immunol. 2022;13:826747.","journal-title":"Front Immunol"},{"key":"2655_CR247","doi-asserted-by":"publisher","first-page":"658753","DOI":"10.3389\/fimmu.2021.658753","volume":"12","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Jiang Y, Xiang S, Kaboli PJ, Shen J, Zhao Y, et al. Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons. Front Immunol. 2021;12:658753.","journal-title":"Front Immunol"},{"key":"2655_CR248","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","volume":"19","author":"S Depil","year":"2020","unstructured":"Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. Off-the-shelf allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185\u201399.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"2655_CR249","doi-asserted-by":"publisher","first-page":"285","DOI":"10.3390\/vaccines13030285","volume":"13","author":"J Puagsopa","year":"2025","unstructured":"Puagsopa J, Tongviseskul N, Jaroentomeechai T, Meksiriporn B. Recent Progress in Developing Extracellular Vesicles as Nanovehicles to Deliver Carbohydrate-Based Therapeutics and Vaccines. Vaccines (Basel). 2025;13(3):285.","journal-title":"Vaccines (Basel)"},{"key":"2655_CR250","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3390\/vaccines10081249","volume":"10","author":"ML Nicol\u00e1s-Morales","year":"2022","unstructured":"Nicol\u00e1s-Morales ML, Luisa-Sanjuan A, Guti\u00e9rrez-Torres M, Vences-Vel\u00e1zquez A, Ortu\u00f1o-Pineda C, Espinoza-Rojo M, et al. Peptide-Based Vaccines in Clinical Phases and New Potential Therapeutic Targets as a New Approach for Breast Cancer: A Review. Vaccines (Basel). 2022;10:1249.","journal-title":"Vaccines (Basel)"},{"issue":"8","key":"2655_CR251","doi-asserted-by":"publisher","first-page":"950","DOI":"10.3390\/vaccines12080950","volume":"12","author":"D Liu","year":"2024","unstructured":"Liu D, Liu L, Li X, Wang S, Wu G, Che X. Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective. Vaccines (Basel). 2024;12(8):950.","journal-title":"Vaccines (Basel)"},{"key":"2655_CR252","doi-asserted-by":"publisher","first-page":"669965","DOI":"10.3389\/fimmu.2021.669965","volume":"12","author":"DA Bernal-Est\u00e9vez","year":"2021","unstructured":"Bernal-Est\u00e9vez DA, Ort\u00edz Barbosa MA, Ort\u00edz-Montero P, Cifuentes C, S\u00e1nchez R, Parra-L\u00f3pez CA. Autologous Dendritic Cells in Combination With Chemotherapy Restore Responsiveness of T Cells in Breast Cancer Patients: A Single-Arm Phase I\/II Trial. Front Immunol. 2021;12:669965.","journal-title":"Front Immunol"},{"key":"2655_CR253","doi-asserted-by":"publisher","first-page":"981","DOI":"10.3390\/cancers16050981","volume":"16","author":"L Hato","year":"2024","unstructured":"Hato L, Vizcay A, Eguren I, P\u00e9rez-Gracia JL, Rodr\u00edguez J, G\u00e1llego P\u00e9rez-Larraya J, et al. Dendritic Cells in Cancer Immunology and Immunotherapy. Cancers (Basel). 2024;16:981.","journal-title":"Cancers (Basel)"},{"key":"2655_CR254","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261\u201379.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2655_CR255","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s12672-025-02542-y","volume":"16","author":"JY Li","year":"2025","unstructured":"Li JY, Jiang RY, Wang J, Wang XJ. Advances in mRNA vaccine therapy for breast cancer research. Discover Oncol. 2025;16(1):673.","journal-title":"Discover Oncol"},{"key":"2655_CR256","doi-asserted-by":"publisher","first-page":"905832","DOI":"10.3389\/fonc.2022.905832","volume":"12","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhou X, Sha H, Xie L, Liu B. Recent Progress on Therapeutic Vaccines for Breast Cancer. Front Oncol. 2022;12:905832.","journal-title":"Front Oncol"},{"key":"2655_CR257","doi-asserted-by":"publisher","first-page":"eabo7604","DOI":"10.1126\/scitranslmed.abo7604","volume":"14","author":"AM D\u2019Alise","year":"2022","unstructured":"D\u2019Alise AM, Brasu N, De Intinis C, Leoni G, Russo V, Langone F, et al. Adenoviral-based vaccine promotes neoantigen-specific CD8\u2009+\u2009T cell stemness and tumor rejection. Sci Transl Med. 2022;14:eabo7604.","journal-title":"Sci Transl Med"},{"key":"2655_CR258","doi-asserted-by":"publisher","first-page":"e2300121","DOI":"10.1002\/advs.202300121","volume":"10","author":"L Diao","year":"2023","unstructured":"Diao L, Liu M. Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell\/tissue Lysate or Whole Tumor Cell. Adv Sci. 2023;10:e2300121.","journal-title":"Adv Sci"},{"key":"2655_CR259","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s00005-019-00566-1","volume":"68","author":"A Arab","year":"2020","unstructured":"Arab A, Yazdian-Robati R, Behravan J. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development. Arch Immunol Ther Exp (Warsz). 2020;68:2.","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"2655_CR260","doi-asserted-by":"publisher","first-page":"3362","DOI":"10.1158\/1078-0432.CCR-22-3578","volume":"29","author":"ML Disis","year":"2023","unstructured":"Disis ML, Dang Y, Coveler AL, Childs JS, Higgins DM, Liu Y, et al. A Phase I\/II Trial of HER2 Vaccine-Primed Autologous T-Cell Infusions in Patients with Treatment Refractory HER2-Overexpressing Breast Cancer. Clin Cancer Res. 2023;29:3362\u201371.","journal-title":"Clin Cancer Res"},{"key":"2655_CR261","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.bbrc.2018.02.092","volume":"497","author":"W Zhang","year":"2018","unstructured":"Zhang W, Wang S, Gu J, Gao Y, Wang Z, Zhang K, et al. Synergistic tumoricidal effect of combined hPD-L1 vaccine and HER2 gene vaccine. Biochem Biophys Res Commun. 2018;497:394\u2013400.","journal-title":"Biochem Biophys Res Commun"},{"key":"2655_CR262","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4161\/hv.26568","volume":"10","author":"S Srivatsan","year":"2014","unstructured":"Srivatsan S, Patel JM, Bozeman EN, Imasuen IE, He S, Daniels D, et al. Allogeneic tumor cell vaccines: the promise and limitations in clinical trials. Hum Vaccin Immunother. 2014;10:52\u201363.","journal-title":"Hum Vaccin Immunother"},{"key":"2655_CR263","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41416-023-02327-6","volume":"129","author":"A P\u00e9rez-Ba\u00f1os","year":"2023","unstructured":"P\u00e9rez-Ba\u00f1os A, Gleisner MA, Flores I, Pereda C, Navarrete M, Araya JP, et al. Whole tumour cell-based vaccines: tuning the instruments to orchestrate an optimal antitumour immune response. Br J Cancer. 2023;129:572\u201385.","journal-title":"Br J Cancer"},{"key":"2655_CR264","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.3892\/ol.2020.11762","volume":"20","author":"Y Liu","year":"2020","unstructured":"Liu Y, Tang L, Gao N, Diao Y, Zhong J, Deng Y, et al. Synthetic MUC1 breast cancer vaccine containing a Toll-like receptor 7 agonist exerts antitumor effects. Oncol Lett. 2020;20:2369\u201377.","journal-title":"Oncol Lett"},{"key":"2655_CR265","doi-asserted-by":"publisher","first-page":"54","DOI":"10.7150\/jca.88261","volume":"15","author":"X Tong","year":"2024","unstructured":"Tong X, Dong C, Liang S. Mucin1 as a potential molecule for cancer immunotherapy and targeted therapy. J Cancer. 2024;15:54\u201367.","journal-title":"J Cancer"},{"key":"2655_CR266","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/cam4.1859","volume":"8","author":"H Zheng","year":"2019","unstructured":"Zheng H, Zhong A, Xie S, Wang Y, Sun J, Zhang J, et al. Elevated serum HER-2 predicts poor prognosis in breast cancer and is correlated to ADAM10 expression. Cancer Med. 2019;8:679\u201385.","journal-title":"Cancer Med"},{"key":"2655_CR267","doi-asserted-by":"publisher","first-page":"1157789","DOI":"10.3389\/fonc.2023.1157789","volume":"13","author":"T Sanomachi","year":"2023","unstructured":"Sanomachi T, Okuma HS, Kitadai R, Kawachi A, Yazaki S, Tokura M, et al. Low HER2 expression is a predictor of poor prognosis in stage I triple-negative breast cancer. Front Oncol. 2023;13:1157789.","journal-title":"Front Oncol"},{"key":"2655_CR268","doi-asserted-by":"publisher","first-page":"e0243550","DOI":"10.1371\/journal.pone.0243550","volume":"15","author":"L Naghibi","year":"2020","unstructured":"Naghibi L, Yazdani M, Momtazi-Borojeni AA, Razazan A, Shariat S, Mansourian M, et al. Preparation of nanoliposomes containing HER2\/neu (P5\u2009+\u2009435) peptide and evaluation of their immune responses and anti-tumoral effects as a prophylactic vaccine against breast cancer. PLoS ONE. 2020;15:e0243550.","journal-title":"PLoS ONE"},{"key":"2655_CR269","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.3390\/cancers13122909","volume":"13","author":"H Hu","year":"2021","unstructured":"Hu H, Steinmetz NF. Development of a Virus-Like Particle-Based Anti-HER2 Breast Cancer Vaccine. Cancers (Basel). 2021;13:2909.","journal-title":"Cancers (Basel)"},{"key":"2655_CR270","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s10549-014-3086-4","volume":"147","author":"EY Gil","year":"2014","unstructured":"Gil EY, Jo UH, Lee HJ, Kang J, Seo JH, Lee ES, et al. Vaccination with ErbB-2 peptides prevents cancer stem cell expansion and suppresses the development of spontaneous tumors in MMTV-PyMT transgenic mice. Breast Cancer Res Treat. 2014;147:69\u201380.","journal-title":"Breast Cancer Res Treat"},{"key":"2655_CR271","doi-asserted-by":"publisher","first-page":"219","DOI":"10.4049\/jimmunol.2300077","volume":"211","author":"BG Vincent","year":"2023","unstructured":"Vincent BG, File DM, McKinnon KP, Moore DT, Frelinger JA, Collins EJ, et al. Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors. J Immunol. 2023;211:219\u201328.","journal-title":"J Immunol"},{"key":"2655_CR272","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.18632\/oncotarget.27998","volume":"12","author":"AE O\u2019Shea","year":"2021","unstructured":"O\u2019Shea AE, Clifton GT, Peoples GE. Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer. Oncotarget. 2021;12:2318\u20139.","journal-title":"Oncotarget"},{"key":"2655_CR273","doi-asserted-by":"publisher","first-page":"e0185099","DOI":"10.1371\/journal.pone.0185099","volume":"12","author":"A Razazan","year":"2017","unstructured":"Razazan A, Behravan J, Arab A, Barati N, Arabi L, Gholizadeh Z, et al. Conjugated nanoliposome with the HER2\/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model. PLoS ONE. 2017;12:e0185099.","journal-title":"PLoS ONE"},{"key":"2655_CR274","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1038\/s41598-018-38371-z","volume":"9","author":"A Razazan","year":"2019","unstructured":"Razazan A, Nicastro J, Slavcev R, Barati N, Arab A, Mosaffa F, et al. Lambda bacteriophage nanoparticles displaying GP2, a HER2\/neu derived peptide, induce prophylactic and therapeutic activities against TUBO tumor model in mice. Sci Rep. 2019;9:2221.","journal-title":"Sci Rep"},{"key":"2655_CR275","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/cncr.24756","volume":"116","author":"MG Carmichael","year":"2010","unstructured":"Carmichael MG, Benavides LC, Holmes JP, Gates JD, Mittendorf EA, Ponniah S, et al. Results of the first phase 1 clinical trial of the HER-2\/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States Military Cancer Institute Clinical Trials Group Study I-04. Cancer. 2010;116:292\u2013301.","journal-title":"Cancer"},{"key":"2655_CR276","doi-asserted-by":"publisher","first-page":"66192","DOI":"10.18632\/oncotarget.11751","volume":"7","author":"EA Mittendorf","year":"2016","unstructured":"Mittendorf EA, Ardavanis A, Litton JK, Shumway NM, Hale DF, Murray JL, et al. Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence. Oncotarget. 2016;7:66192\u2013201.","journal-title":"Oncotarget"},{"key":"2655_CR277","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1245\/ASO.2006.03.069","volume":"13","author":"EA Mittendorf","year":"2006","unstructured":"Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE. Investigating the combination of trastuzumab and HER2\/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol. 2006;13:1085\u201398.","journal-title":"Ann Surg Oncol"},{"key":"2655_CR278","doi-asserted-by":"publisher","first-page":"5374","DOI":"10.1158\/0008-5472.CAN-16-2774","volume":"77","author":"VA Gall","year":"2017","unstructured":"Gall VA, Philips AV, Qiao N, Clise-Dwyer K, Perakis AA, Zhang M, et al. Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. Cancer Res. 2017;77:5374\u201383.","journal-title":"Cancer Res"},{"key":"2655_CR279","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10549-020-05638-x","volume":"181","author":"TA Brown","year":"2020","unstructured":"Brown TA, Mittendorf EA, Hale DF, Myers JW, Peace KM, Jackson DO, et al. Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence. Breast Cancer Res Treat. 2020;181:391\u2013401.","journal-title":"Breast Cancer Res Treat"},{"key":"2655_CR280","doi-asserted-by":"publisher","first-page":"4054","DOI":"10.4049\/jimmunol.171.8.4054","volume":"171","author":"MH Manjili","year":"2003","unstructured":"Manjili MH, Wang X-Y, Chen X, Martin T, Repasky EA, Henderson R, et al. HSP110-HER2\/neu chaperone complex vaccine induces protective immunity against spontaneous mammary tumors in HER-2\/neu transgenic mice. J Immunol. 2003;171:4054\u201361.","journal-title":"J Immunol"},{"key":"2655_CR281","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.canlet.2014.11.029","volume":"357","author":"C Panis","year":"2015","unstructured":"Panis C, Pizzatti L, Corr\u00eaa S, Binato R, Lemos GF, da Silva do Amaral, Herrera AC, et al. The positive is inside the negative: HER2-negative tumors can express the HER2 intracellular domain and present a HER2-positive phenotype. Cancer Lett. 2015;357:186\u201395.","journal-title":"Cancer Lett"},{"key":"2655_CR282","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1007\/s00262-003-0463-y","volume":"53","author":"ME Gillogly","year":"2004","unstructured":"Gillogly ME, Kallinteris NL, Xu M, Gulfo JV, Humphreys RE, Murray JL. Ii-Key\/HER-2\/neu MHC class-II antigenic epitope vaccine peptide for breast cancer. Cancer Immunol Immunother. 2004;53:490\u20136.","journal-title":"Cancer Immunol Immunother"},{"issue":"30","key":"2655_CR283","doi-asserted-by":"publisher","first-page":"10616","DOI":"10.1002\/chem.201500831","volume":"21","author":"A Fern\u00e1ndez-Tejada","year":"2015","unstructured":"Fern\u00e1ndez-Tejada A, Ca\u00f1ada FJ, Jim\u00e9nez-Barbero J. Recent Developments in Synthetic Carbohydrate-Based Diagnostics, Vaccines, and Therapeutics. Chemistry. 2015;21(30):10616\u201328.","journal-title":"Chemistry"},{"key":"2655_CR284","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nrc3982","volume":"15","author":"SS Pinho","year":"2015","unstructured":"Pinho SS, Reis CA. Glycosylation in cancer: Mechanisms and clinical implications. Nat Rev Cancer. 2015;15:540\u201355.","journal-title":"Nat Rev Cancer"},{"key":"2655_CR285","doi-asserted-by":"publisher","first-page":"742831","DOI":"10.1155\/2014\/742831","volume":"2014","author":"FM Tuccillo","year":"2014","unstructured":"Tuccillo FM, De Laurentiis A, Palmieri C, Fiume G, Bonelli P, Borrelli A, et al. Aberrant glycosylation as biomarker for cancer: focus on CD43. Biomed Res Int. 2014;2014:742831.","journal-title":"Biomed Res Int"},{"issue":"1","key":"2655_CR286","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12929-019-0591-0","volume":"27","author":"R Mettu","year":"2020","unstructured":"Mettu R, Chen CY, Wu CY. Synthetic carbohydrate-based vaccines: challenges and opportunities. J Biomed Sci. 2020;27(1):9.","journal-title":"J Biomed Sci"},{"key":"2655_CR287","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","volume":"15","author":"MA Cheever","year":"2009","unstructured":"Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15:5323\u201337.","journal-title":"Clin Cancer Res"},{"key":"2655_CR288","doi-asserted-by":"publisher","first-page":"7107","DOI":"10.1002\/ANIE.201702191","volume":"56","author":"J Zheng","year":"2017","unstructured":"Zheng J, Xiao H, Wu R. Specific Identification of Glycoproteins Bearing the Tn Antigen in Human Cells. Angew Chem Int Ed Engl. 2017;56:7107\u201311. https:\/\/doi.org\/10.1002\/ANIE.201702191.","journal-title":"Angew Chem Int Ed Engl"},{"key":"2655_CR289","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1021\/ml5003794","volume":"5","author":"C Nativi","year":"2014","unstructured":"Nativi C, Renaudet O. Recent progress in antitumoral synthetic vaccines. ACS Med Chem Lett. 2014;5:1176\u20138.","journal-title":"ACS Med Chem Lett"},{"key":"2655_CR290","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1002\/tcr.202100182","volume":"21","author":"N Stergiou","year":"2021","unstructured":"Stergiou N, Urschbach M, Gabba A, Schmitt E, Kunz H, Besenius P. The Development of Vaccines from Synthetic Tumor-Associated Mucin Glycopeptides and their Glycosylation-Dependent Immune Response. Chem Rec. 2021;21:3313\u201331.","journal-title":"Chem Rec"},{"key":"2655_CR291","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1634\/THEONCOLOGIST.2010-0307","volume":"16","author":"D Miles","year":"2011","unstructured":"Miles D, Roch\u00e9 H, Martin M, Perren TJ, Cameron DA, Glaspy J, et al. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011;16:1092\u2013100. https:\/\/doi.org\/10.1634\/THEONCOLOGIST.2010-0307.","journal-title":"Oncologist"},{"key":"2655_CR292","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10719-019-09884-0","volume":"36","author":"C Song","year":"2019","unstructured":"Song C, Zheng XJ, Guo H, Cao Y, Zhang F, Li Q, et al. Fluorine-modified sialyl-Tn-CRM197 vaccine elicits a robust immune response. Glycoconj J. 2019;36:399\u2013408.","journal-title":"Glycoconj J"},{"key":"2655_CR293","doi-asserted-by":"publisher","first-page":"7729","DOI":"10.1039\/C9CC02920F","volume":"55","author":"C Nativi","year":"2019","unstructured":"Nativi C, Papi F, Roelens S. Tn antigen analogues: the synthetic way to upgrade an attracting tumour associated carbohydrate antigen (TACA). Chem Commun (Camb). 2019;55:7729\u201336.","journal-title":"Chem Commun (Camb)"},{"key":"2655_CR294","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1021\/jacs.8b13503","volume":"141","author":"I Compani\u00f3n","year":"2019","unstructured":"Compani\u00f3n I, Guerreiro A, Mangini V, Castro-L\u00f3pez J, Escudero-Casao M, Avenoza A, et al. Structure-Based Design of Potent Tumor-Associated Antigens: Modulation of Peptide Presentation by Single-Atom O\/S or O\/Se Substitutions at the Glycosidic Linkage. J Am Chem Soc. 2019;141:4063\u201372.","journal-title":"J Am Chem Soc"},{"key":"2655_CR295","doi-asserted-by":"publisher","first-page":"13027","DOI":"10.1021\/jacs.2c12843","volume":"145","author":"A Gabba","year":"2023","unstructured":"Gabba A, Attariya R, Behren S, Pett C, van der Horst JC, Yurugi H, et al. MUC1 Glycopeptide Vaccine Modified with a GalNAc Glycocluster Targets the Macrophage Galactose C-type Lectin on Dendritic Cells to Elicit an Improved Humoral Response. J Am Chem Soc. 2023;145:13027\u201337.","journal-title":"J Am Chem Soc"},{"issue":"1","key":"2655_CR296","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41541-025-01127-8","volume":"10","author":"E Pesce","year":"2025","unstructured":"Pesce E, Sodini A, Palmieri E, Valensin S, Tinti C, Rossi M, et al. GMMA decorated with mucin 1 Tn\/STn mimetics elicit specific antibodies response and inhibit tumor growth. NPJ Vaccines. 2025;10(1):71.","journal-title":"NPJ Vaccines"},{"issue":"49","key":"2655_CR297","doi-asserted-by":"publisher","first-page":"e202411009","DOI":"10.1002\/anie.202411009","volume":"63","author":"A Guerreiro","year":"2024","unstructured":"Guerreiro A, Compa\u00f1\u00f3n I, Lazaris FS, Lab\u00e3o-Almeida C, Oroz P, Ghirardello M, et al. Non-Natural MUC1 Glycopeptide Homogeneous Cancer Vaccine with Enhanced Immunogenicity and Therapeutic Activity. Angew Chem Int Ed Engl. 2024;63(49):e202411009.","journal-title":"Angew Chem Int Ed Engl"},{"key":"2655_CR298","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3892\/ijo.2016.3386","volume":"48","author":"M Antonilli","year":"2016","unstructured":"Antonilli M, Rahimi H, Visconti V, Napoletano C, Ruscito I, Zizzari IG, et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I\/II clinical trial. Int J Oncol. 2016;48:1369\u201378.","journal-title":"Int J Oncol"},{"key":"2655_CR299","doi-asserted-by":"publisher","first-page":"2760","DOI":"10.1111\/cas.14510","volume":"111","author":"U Toh","year":"2020","unstructured":"Toh U, Sakurai S, Saku S, Takao Y, Okabe M, Iwakuma N, et al. Early phase II study of mixed 19-peptide vaccine monotherapy for refractory triple-negative breast cancer. Cancer Sci. 2020;111:2760\u20139.","journal-title":"Cancer Sci"},{"key":"2655_CR300","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1111\/imm.13643","volume":"169","author":"W Shi","year":"2023","unstructured":"Shi W, Tong Z, Chen S, Qiu Q, Zhou J, Qian H. Development of novel self-assembled vaccines based on tumour-specific antigenic peptide and TLR2 agonist for effective breast cancer immunotherapy via activating CD8\u2009+\u2009T cells and enhancing their function. Immunology. 2023;169:454\u201366.","journal-title":"Immunology"},{"key":"2655_CR301","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12935-024-03421-2","volume":"24","author":"L Cen","year":"2024","unstructured":"Cen L, Zhang Z, Sun Y, Wu N, Shao J, Qian Z, et al. Efficacy of MAGE-A4 long peptide as a universal immunoprevention cancer vaccine. Cancer Cell Int. 2024;24:232.","journal-title":"Cancer Cell Int"},{"key":"2655_CR302","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41523-025-00742-x","volume":"11","author":"H Soliman","year":"2025","unstructured":"Soliman H, Aldrich A, Abdo N, Han H, Soyano A, Costa R, et al. A pilot study incorporating HER2-directed dendritic cells into neoadjuvant therapy of early stage HER2\u2009+\u2009ER- breast cancer. NPJ Breast Cancer. 2025;11:29.","journal-title":"NPJ Breast Cancer"},{"key":"2655_CR303","doi-asserted-by":"publisher","first-page":"110888","DOI":"10.1016\/j.biopha.2020.110888","volume":"132","author":"T Gao","year":"2020","unstructured":"Gao T, Cen Q, Lei H. A review on development of MUC1-based cancer vaccine. Biomed Pharmacotherapy. 2020;132:110888.","journal-title":"Biomed Pharmacotherapy"},{"key":"2655_CR304","doi-asserted-by":"publisher","first-page":"7509","DOI":"10.3390\/ijms25147509","volume":"25","author":"S Zanotta","year":"2024","unstructured":"Zanotta S, Galati D, De Filippi R, Pinto A. Enhancing Dendritic Cell Cancer Vaccination: The Synergy of Immune Checkpoint Inhibitors in Combined Therapies. Int J Mol Sci. 2024;25:7509.","journal-title":"Int J Mol Sci"},{"key":"2655_CR305","doi-asserted-by":"publisher","first-page":"1368103","DOI":"10.3389\/fimmu.2024.1368103","volume":"15","author":"BJ Koeneman","year":"2024","unstructured":"Koeneman BJ, Schreibelt G, Gorris MAJ, Hins-de Bree S, Westdorp H, Ottevanger PB, et al. Dendritic cell vaccination combined with carboplatin\/paclitaxel for metastatic endometrial cancer patients: results of a phase I\/II trial. Front Immunol. 2024;15:1368103.","journal-title":"Front Immunol"},{"key":"2655_CR306","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.21873\/anticanres.17196","volume":"44","author":"T Kamigaki","year":"2024","unstructured":"Kamigaki T, Takimoto R, Okada S, Ibe H, Oguma E, Goto S. Personalized Dendritic-cell-based Vaccines Targeting Cancer Neoantigens. Anticancer Res. 2024;44:3713\u201324.","journal-title":"Anticancer Res"},{"key":"2655_CR307","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13073-024-01388-3","volume":"16","author":"X Zhang","year":"2024","unstructured":"Zhang X, Goedegebuure SP, Chen MY, Mishra R, Zhang F, Yu YY, et al. Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients. Genome Med. 2024;16:131.","journal-title":"Genome Med"},{"key":"2655_CR308","doi-asserted-by":"publisher","first-page":"1433185","DOI":"10.3389\/fimmu.2024.1433185","volume":"15","author":"S Tadic","year":"2024","unstructured":"Tadic S, Mart\u00ednez A. Nucleic acid cancer vaccines targeting tumor related angiogenesis. Could mRNA vaccines constitute a game changer? Front Immunol. 2024;15:1433185.","journal-title":"Front Immunol"},{"key":"2655_CR309","doi-asserted-by":"publisher","first-page":"9435","DOI":"10.1007\/s00432-023-04805-z","volume":"149","author":"XT Jiang","year":"2023","unstructured":"Jiang XT, Liu Q. mRNA vaccination in breast cancer: current progress and future direction. J Cancer Res Clin Oncol. 2023;149:9435\u201350.","journal-title":"J Cancer Res Clin Oncol"},{"key":"2655_CR310","doi-asserted-by":"crossref","unstructured":"Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell. 2017;170:1109-19.e10.","DOI":"10.1016\/j.cell.2017.08.027"},{"key":"2655_CR311","doi-asserted-by":"publisher","first-page":"1375433","DOI":"10.3389\/fimmu.2024.1375433","volume":"15","author":"H Chowaniec","year":"2024","unstructured":"Chowaniec H, \u015alubowska A, Mroczek M, Borowczyk M, Braszka M, Dworacki G, et al. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy. Front Immunol. 2024;15:1375433.","journal-title":"Front Immunol"},{"issue":"16","key":"2655_CR312","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.3390\/cancers15164178","volume":"15","author":"C Lovatt","year":"2023","unstructured":"Lovatt C, Parker AL. Oncolytic Viruses and Immune Checkpoint Inhibitors: The Hot New Power Couple. Cancers (Basel). 2023;15(16):4178.","journal-title":"Cancers (Basel)"},{"key":"2655_CR313","doi-asserted-by":"publisher","first-page":"826302","DOI":"10.3389\/fmolb.2022.826302","volume":"9","author":"ME Carter","year":"2022","unstructured":"Carter ME, Hartkopf AD, Wagner A, Volmer LL, Brucker SY, Berchtold S, et al. A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy. Front Mol Biosci. 2022;9:826302.","journal-title":"Front Mol Biosci"},{"key":"2655_CR314","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1002\/jcp.27150","volume":"234","author":"A Arab","year":"2019","unstructured":"Arab A, Behravan N, Razazan A, Barati N, Mosaffa F, Nicastro J, et al. The viral approach to breast cancer immunotherapy. J Cell Physiol. 2019;234:1257\u201367.","journal-title":"J Cell Physiol"},{"key":"2655_CR315","doi-asserted-by":"publisher","first-page":"115209","DOI":"10.1016\/j.bcp.2022.115209","volume":"204","author":"AT Jacobs","year":"2022","unstructured":"Jacobs AT, Martinez Castaneda-Cruz D, Rose MM, Connelly L. Targeted therapy for breast cancer: An overview of drug classes and outcomes. Biochem Pharmacol. 2022;204:115209.","journal-title":"Biochem Pharmacol"},{"key":"2655_CR316","doi-asserted-by":"publisher","first-page":"102831","DOI":"10.1016\/j.ctrv.2024.102831","volume":"130","author":"F Rebaudi","year":"2024","unstructured":"Rebaudi F, De Franco F, Goda R, Obino V, Vita G, Baronti C, et al. The landscape of combining immune checkpoint inhibitors with novel Therapies: Secret alliances against breast cancer. Cancer Treat Rev. 2024;130:102831.","journal-title":"Cancer Treat Rev"},{"key":"2655_CR317","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10549-022-06780-4","volume":"197","author":"T Gupta","year":"2023","unstructured":"Gupta T, Vinayak S, Telli M. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer. Breast Cancer Res Treat. 2023;197:51\u20136.","journal-title":"Breast Cancer Res Treat"},{"key":"2655_CR318","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","volume":"44","author":"A Jain","year":"2025","unstructured":"Jain A, Barge A, Parris CN. Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms. Oncogene. 2025;44:193\u2013207.","journal-title":"Oncogene"},{"key":"2655_CR319","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1200\/JCO.2024.42.16_suppl.608","volume":"42","author":"S Loi","year":"2024","unstructured":"Loi S, Francis PA, Zdenkowski N, Gebski V, Fox SB, White M, et al. Phase II study of neoadjuvant ipilimumab and nivolumab in combination with paclitaxel following anthracycline-based chemotherapy in patients with treatment resistant stage III triple negative breast cancer (TNBC): BCT1702 - Survival results. J Clin Oncol. 2024;42:608.","journal-title":"J Clin Oncol"},{"issue":"134","key":"2655_CR320","doi-asserted-by":"publisher","first-page":"134ra62","DOI":"10.1126\/scitranslmed.3003330","volume":"4","author":"AJ Rech","year":"2012","unstructured":"Rech AJ, Mick R, Martin S, Recio A, Aqui NA, Powell DJ, et al. CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. Sci Transl Med. 2012;4(134):134ra62.","journal-title":"Sci Transl Med"},{"issue":"Suppl 13","key":"2655_CR321","doi-asserted-by":"publisher","first-page":"CT207","DOI":"10.1158\/1538-7445.AM2021-CT207","volume":"81","author":"J Powderly","year":"2021","unstructured":"Powderly J, Shimizu T, LoRusso P, Razak A, Miller K, Balar A, et al. Abstract CT207: Phase 1 first-in-human study of ABBV-151 as monotherapy or in combination with budigalimab in patients with locally advanced or metastatic solid tumors. Cancer Res. 2021;81(Suppl 13):CT207\u2013207.","journal-title":"Cancer Res"},{"key":"2655_CR322","doi-asserted-by":"publisher","first-page":"4548","DOI":"10.1021\/acs.jmedchem.3c00030","volume":"66","author":"Y Wu","year":"2023","unstructured":"Wu Y, Xi J, Li Y, Li Z, Zhang Y, Wang J, et al. Discovery of a Potent and Selective CCR8 Small Molecular Antagonist IPG7236 for the Treatment of Cancer. J Med Chem. 2023;66:4548\u201364.","journal-title":"J Med Chem"},{"key":"2655_CR323","doi-asserted-by":"publisher","first-page":"121180","DOI":"10.1016\/j.biomaterials.2021.121180","volume":"279","author":"J Guan","year":"2021","unstructured":"Guan J, Wu Y, Liu X, Wang H, Ye N, Li Z, et al. A novel prodrug and its nanoformulation suppress cancer stem cells by inducing immunogenic cell death and inhibiting indoleamine 2,3-dioxygenase. Biomaterials. 2021;279:121180.","journal-title":"Biomaterials"},{"key":"2655_CR324","doi-asserted-by":"publisher","first-page":"5150","DOI":"10.4049\/jimmunol.1001114","volume":"185","author":"N Casares","year":"2010","unstructured":"Casares N, Rudilla F, Arribillaga L, Llopiz D, Riezu-Boj JI, Lozano T, et al. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice. J Immunol. 2010;185:5150\u20139.","journal-title":"J Immunol"},{"key":"2655_CR325","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10549-017-4414-2","volume":"166","author":"MA Moreno Ayala","year":"2017","unstructured":"Moreno Ayala MA, Gottardo MF, Imsen M, Asad AS, Bal de Kier Joff\u00e9 E, Casares N, et al. Therapeutic blockade of Foxp3 in experimental breast cancer models. Breast Cancer Res Treat. 2017;166:393\u2013405.","journal-title":"Breast Cancer Res Treat"},{"key":"2655_CR326","doi-asserted-by":"publisher","first-page":"101884","DOI":"10.1016\/j.nantod.2023.101884","volume":"51","author":"C Lim","year":"2023","unstructured":"Lim C, Hwang D, Yazdimamaghani M, Atkins HM, Hyun H, Shin Y, et al. High-Dose Paclitaxel and its Combination with CSF1R Inhibitor in Polymeric Micelles for Chemoimmunotherapy of Triple Negative Breast Cancer. Nano Today. 2023;51:101884.","journal-title":"Nano Today"},{"key":"2655_CR327","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2147\/IJN.S440332","volume":"19","author":"C Hu","year":"2024","unstructured":"Hu C, Liu Y, Cao W, Li N, Gao S, Wang Z, et al. Efficacy and Mechanism of a Biomimetic Nanosystem Carrying Doxorubicin and an IDO Inhibitor for Treatment of Advanced Triple-Negative Breast Cancer. Int J Nanomed. 2024;19:507\u201326.","journal-title":"Int J Nanomed"},{"key":"2655_CR328","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41523-022-00471-5","volume":"8","author":"C Pantelidou","year":"2022","unstructured":"Pantelidou C, Jadhav H, Kothari A, Liu R, Wulf GM, Guerriero JL, et al. STING agonism enhances anti-tumor immune responses and therapeutic efficacy of PARP inhibition in BRCA-associated breast cancer. NPJ Breast Cancer. 2022;8:102.","journal-title":"NPJ Breast Cancer"},{"key":"2655_CR329","doi-asserted-by":"publisher","first-page":"100839","DOI":"10.1016\/j.mtbio.2023.100839","volume":"23","author":"C Huang","year":"2023","unstructured":"Huang C, Shao N, Huang Y, Chen J, Wang D, Hu G, et al. Overcoming challenges in the delivery of STING agonists for cancer immunotherapy: A comprehensive review of strategies and future perspectives. Mater Today Bio. 2023;23:100839.","journal-title":"Mater Today Bio"},{"key":"2655_CR330","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s00262-019-02444-3","volume":"69","author":"N Erin","year":"2020","unstructured":"Erin N, Dilma\u00e7 S, Curry A, Duymu\u015f \u00d6, Tanriover G, Prodeus A, et al. CD200 mimetic aptamer PEG-M49 markedly increases the therapeutic effects of pegylated liposomal doxorubicin in a mouse model of metastatic breast carcinoma: an effect independent of CD200 receptor 1. Cancer Immunol Immunother. 2020;69:103\u201314.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"2655_CR331","doi-asserted-by":"publisher","first-page":"e011322","DOI":"10.1136\/jitc-2024-011322","volume":"13","author":"K Kyritsi","year":"2025","unstructured":"Kyritsi K, Pacholczyk R, Douglass E, Yu M, Fang H, Zhou G, et al. \u03b2-blocker suppresses both tumoral sympathetic neurons and perivascular macrophages during oncolytic herpes virotherapy. J Immunother Cancer. 2025;13(4):e011322.","journal-title":"J Immunother Cancer"},{"key":"2655_CR332","doi-asserted-by":"publisher","first-page":"120305","DOI":"10.1016\/j.lfs.2022.120305","volume":"291","author":"N Erin","year":"2022","unstructured":"Erin N, Akman M, Aliyev E, Tanr\u0131\u00f6ver G, Korcum AF. Olvanil activates sensory nerve fibers, increases T cell response and decreases metastasis of breast carcinoma. Life Sci. 2022;291:120305.","journal-title":"Life Sci"},{"key":"2655_CR333","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1158\/2159-8290.CD-20-1815","volume":"11","author":"VS Pelly","year":"2021","unstructured":"Pelly VS, Moeini A, Roelofsen LM, Bonavita E, Bell CR, Hutton C, et al. Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy. Cancer Discov. 2021;11:2602\u201319.","journal-title":"Cancer Discov"},{"key":"2655_CR334","doi-asserted-by":"publisher","first-page":"19147","DOI":"10.18632\/oncotarget.24931","volume":"9","author":"N Erin","year":"2018","unstructured":"Erin N, Tanri\u00f6ver G, Curry A, Akman M, Duymus \u00d6, Gorczynski R. CD200fc enhances anti-tumoral immune response and inhibits visceral metastasis of breast carcinoma. Oncotarget. 2018;9:19147\u201358.","journal-title":"Oncotarget"},{"issue":"2","key":"2655_CR335","doi-asserted-by":"publisher","first-page":"e000764","DOI":"10.1136\/jitc-2020-000764","volume":"8","author":"LA Marshall","year":"2020","unstructured":"Marshall LA, Marubayashi S, Jorapur A, Jacobson S, Zibinsky M, Robles O, et al. Tumors establish resistance to immunotherapy by regulating Treg recruitment via CCR4. J Immunother Cancer. 2020;8(2):e000764.","journal-title":"J Immunother Cancer"},{"issue":"7","key":"2655_CR336","doi-asserted-by":"publisher","first-page":"e2114282119","DOI":"10.1073\/pnas.2114282119","volume":"119","author":"Y Kidani","year":"2022","unstructured":"Kidani Y, Nogami W, Yasumizu Y, Kawashima A, Tanaka A, Sonoda Y, et al. CCR8-targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long-lasting memory. Proc Natl Acad Sci U S A. 2022;119(7):e2114282119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2655_CR337","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ebiom.2017.10.009","volume":"25","author":"Y Kunisada","year":"2017","unstructured":"Kunisada Y, Eikawa S, Tomonobu N, Domae S, Uehara T, Hori S, et al. Attenuation of CD4\u2009+\u2009CD25+ Regulatory T Cells in the Tumor Microenvironment by Metformin, a Type 2 Diabetes Drug. EBioMedicine. 2017;25:154\u201364.","journal-title":"EBioMedicine"},{"issue":"9","key":"2655_CR338","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.3390\/v15091813","volume":"15","author":"AJ Nicola Candia","year":"2023","unstructured":"Nicola Candia AJ, Garcia Fallit M, Pe\u00f1a Agudelo JA, P\u00e9rez K\u00fcper M, Gonzalez N, Moreno Ayala MA, et al. Targeting FOXP3 Tumor-Intrinsic Effects Using Adenoviral Vectors in Experimental Breast Cancer. Viruses. 2023;15(9):1813.","journal-title":"Viruses"},{"key":"2655_CR339","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s40364-024-00714-6","volume":"12","author":"Z Guo","year":"2024","unstructured":"Guo Z, Zhu Z, Lin X, Wang S, Wen Y, Wang L, et al. Tumor microenvironment and immunotherapy for triple-negative breast cancer. Biomark Res. 2024;12:166.","journal-title":"Biomark Res"},{"issue":"1","key":"2655_CR340","doi-asserted-by":"publisher","first-page":"1777625","DOI":"10.1080\/2162402X.2020.1777625","volume":"9","author":"J Le Naour","year":"2020","unstructured":"Le Naour J, Galluzzi L, Zitvogel L, Kroemer G, Vacchelli E. Trial watch: IDO inhibitors in cancer therapy. Oncoimmunology. 2020;9(1):1777625.","journal-title":"Oncoimmunology"},{"issue":"1","key":"2655_CR341","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","volume":"5","author":"MA Cannarile","year":"2017","unstructured":"Cannarile MA, Weisser M, Jacob W, Jegg AM, Ries CH, R\u00fcttinger D. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J Immunother Cancer. 2017;5(1):53.","journal-title":"J Immunother Cancer"},{"issue":"13","key":"2655_CR342","doi-asserted-by":"publisher","first-page":"e184422","DOI":"10.1172\/JCI184422","volume":"135","author":"L Kalfeist","year":"2025","unstructured":"Kalfeist L, Ledys F, Petit S, Poirrier C, Mohammed SK, Galland L, et al. Co-targeting TGF-\u03b2 and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet. J Clin Invest. 2025;135(13):e184422.","journal-title":"J Clin Invest"},{"key":"2655_CR343","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.cell.2022.02.015","volume":"185","author":"M Dhainaut","year":"2022","unstructured":"Dhainaut M, Rose SA, Akturk G, Wroblewska A, Nielsen SR, Park ES, et al. Spatial CRISPR genomics identifies regulators of the tumor microenvironment. Cell. 2022;185:1223\u2013e3920.","journal-title":"Cell"},{"key":"2655_CR344","doi-asserted-by":"publisher","first-page":"605","DOI":"10.3389\/fcell.2020.00605","volume":"8","author":"AF Teixeira","year":"2020","unstructured":"Teixeira AF, ten Dijke P, Zhu HJ. On-Target Anti-TGF-\u03b2 Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges? Front Cell Dev Biol. 2020;8:605.","journal-title":"Front Cell Dev Biol"},{"issue":"21","key":"2655_CR345","doi-asserted-by":"publisher","first-page":"e40118","DOI":"10.1016\/j.heliyon.2024.e40118","volume":"10","author":"F Du","year":"2024","unstructured":"Du F, Li J, Zhong X, Zhang Z, Zhao Y. Endothelial-to-mesenchymal transition in the tumor microenvironment: Roles of transforming growth factor-\u03b2 and matrix metalloproteins. Heliyon. 2024;10(21):e40118.","journal-title":"Heliyon"},{"key":"2655_CR346","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s10549-018-4752-8","volume":"170","author":"N Erin","year":"2018","unstructured":"Erin N, Ogan N, Yerlikaya A. Secretomes reveal several novel proteins as well as TGF-\u03b21 as the top upstream regulator of metastatic process in breast cancer. Breast Cancer Res Treat. 2018;170:235\u201350.","journal-title":"Breast Cancer Res Treat"},{"issue":"639","key":"2655_CR347","doi-asserted-by":"publisher","first-page":"eaba3880","DOI":"10.1126\/scisignal.aba3880","volume":"13","author":"C Anastasi","year":"2020","unstructured":"Anastasi C, Rousselle P, Talantikite M, Tessier A, Cluzel C, Bachmann A, et al. BMP-1 disrupts cell adhesion and enhances TGF-\u03b2 activation through cleavage of the matricellular protein thrombospondin-1. Sci Signal. 2020;13(639):eaba3880.","journal-title":"Sci Signal"},{"key":"2655_CR348","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41586-023-06568-6","volume":"622","author":"AM Globig","year":"2023","unstructured":"Globig AM, Zhao S, Roginsky J, Maltez VI, Guiza J, Avina-Ochoa N, et al. The \u03b21-adrenergic receptor links sympathetic nerves to T cell exhaustion. Nature. 2023;622:383\u201392.","journal-title":"Nature"},{"key":"2655_CR349","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijms21217958","volume":"21","author":"B Mravec","year":"2020","unstructured":"Mravec B, Horvathova L, Hunakova L. Neurobiology of Cancer: the Role of \u03b2-Adrenergic Receptor Signaling in Various Tumor Environments. Int J Mol Sci. 2020;21:1\u201324.","journal-title":"Int J Mol Sci"},{"key":"2655_CR350","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1182\/blood-2012-07-446054","volume":"121","author":"BM Janelsins","year":"2013","unstructured":"Janelsins BM, Sumpter TL, Tkacheva OA, Rojas-Canales DM, Erdos G, Mathers AR, et al. Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12. Blood. 2013;121:2923\u201333.","journal-title":"Blood"},{"key":"2655_CR351","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.bbi.2015.02.024","volume":"48","author":"N Erin","year":"2015","unstructured":"Erin N, Korcum AF, Tanri\u00f6ver G, Kale \u015e, Demir N, K\u00f6ksoy S. Activation of neuroimmune pathways increases therapeutic effects of radiotherapy on poorly differentiated breast carcinoma. Brain Behav Immun. 2015;48:174\u201385.","journal-title":"Brain Behav Immun"},{"key":"2655_CR352","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51:27\u201341.","journal-title":"Immunity"},{"key":"2655_CR353","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.immuni.2019.06.021","volume":"51","author":"S Shalapour","year":"2019","unstructured":"Shalapour S, Karin M. Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation. Immunity. 2019;51:15\u201326.","journal-title":"Immunity"},{"key":"2655_CR354","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00540-018-2579-4","volume":"33","author":"M Matsuda","year":"2019","unstructured":"Matsuda M, Huh Y, Ji RR. Roles of inflammation, neurogenic inflammation, and neuroinflammation in pain. J Anesth. 2019;33:131\u20139.","journal-title":"J Anesth"},{"issue":"1","key":"2655_CR355","doi-asserted-by":"publisher","first-page":"oyae081","DOI":"10.1093\/oncolo\/oyae081","volume":"30","author":"R Giusti","year":"2025","unstructured":"Giusti R, Porzio G, Maltoni M, Filetti M, Cuomo A, Bandieri E, et al. Association of opioid use with survival in patients with cancer treated with immune checkpoint inhibitors: it is time for evidence-based behaviors. Oncologist. 2025;30(1):oyae081.","journal-title":"Oncologist"},{"key":"2655_CR356","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1038\/onc.2014.317","volume":"34","author":"N Erin","year":"2015","unstructured":"Erin N, Podnos A, Tanriover G, Duymu\u015f, Cote E, Khatri I, et al. Bidirectional effect of CD200 on breast cancer development and metastasis, with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response. Oncogene. 2015;34:3860\u201370.","journal-title":"Oncogene"},{"key":"2655_CR357","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.3332\/ecancer.2020.1148","volume":"14","author":"S Morganti","year":"2020","unstructured":"Morganti S, Curigliano G. Combinations using checkpoint blockade to overcome resistance. Ecancermedicalscience. 2020;14:1148.","journal-title":"Ecancermedicalscience"},{"key":"2655_CR358","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","volume":"38","author":"A Rotte","year":"2019","unstructured":"Rotte A. Combination of CTLA-4 and PD-1 blockers for treatment of cancer. J Exp Clin Cancer Res. 2019;38:255.","journal-title":"J Exp Clin Cancer Res"},{"key":"2655_CR359","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1186\/s12967-020-02421-w","volume":"18","author":"JA Kyte","year":"2020","unstructured":"Kyte JA, Andresen NK, Russnes HG, Fretland S, Falk RS, Lingj\u00e6rde OC, et al. ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer. J Transl Med. 2020;18:269.","journal-title":"J Transl Med"},{"key":"2655_CR360","doi-asserted-by":"publisher","first-page":"3223","DOI":"10.1038\/s41591-024-03249-3","volume":"30","author":"I Nederlof","year":"2024","unstructured":"Nederlof I, Isaeva OI, de Graaf M, Gielen RCAM, Bakker NAM, Rolfes AL, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial. Nat Med. 2024;30:3223\u201335.","journal-title":"Nat Med"},{"key":"2655_CR361","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1080\/21645515.2020.1754691","volume":"16","author":"CD Pack","year":"2020","unstructured":"Pack CD, Bommireddy R, Munoz LE, Patel JM, Bozeman EN, Dey P, et al. Tumor membrane-based vaccine immunotherapy in combination with anti-CTLA-4 antibody confers protection against immune checkpoint resistant murine triple-negative breast cancer. Hum Vaccin Immunother. 2020;16:3184\u201393.","journal-title":"Hum Vaccin Immunother"},{"key":"2655_CR362","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","volume":"403","author":"JS Weber","year":"2024","unstructured":"Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403:632\u201344.","journal-title":"Lancet"},{"key":"2655_CR363","doi-asserted-by":"publisher","first-page":"1325615","DOI":"10.3389\/fimmu.2023.1325615","volume":"14","author":"J Yin","year":"2024","unstructured":"Yin J, Gu T, Chaudhry N, Davidson NE, Huang Y. Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications. Front Immunol. 2024;14:1325615.","journal-title":"Front Immunol"},{"key":"2655_CR364","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1158\/2159-8290.CD-19-1510","volume":"10","author":"A Diab","year":"2020","unstructured":"Diab A, Tannir NM, Bentebibel SE, Hwu P, Papadimitrakopoulou V, Haymaker C, et al. Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). Cancer Discov. 2020;10:1158\u201373.","journal-title":"Cancer Discov"},{"key":"2655_CR365","doi-asserted-by":"publisher","first-page":"175883592312048","DOI":"10.1177\/17588359231204854","volume":"15","author":"J Huang","year":"2023","unstructured":"Huang J, Gong C, Zhou A. Modulation of gut microbiota: a novel approach to enhancing the effects of immune checkpoint inhibitors. Ther Adv Med Oncol. 2023;15:17588359231204854.","journal-title":"Ther Adv Med Oncol"},{"key":"2655_CR366","doi-asserted-by":"publisher","first-page":"102254","DOI":"10.3389\/fonc.2022.1022542","volume":"12","author":"KM Jungles","year":"2022","unstructured":"Jungles KM, Holcomb EA, Pearson AN, Jungles KR, Bishop CR, Pierce LJ, et al. Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer. Front Oncol. 2022;12:102254.","journal-title":"Front Oncol"},{"key":"2655_CR367","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.semradonc.2022.01.001","volume":"32","author":"CA Santa-Maria","year":"2022","unstructured":"Santa-Maria CA, Dunn SA, Ho AY. Immunotherapy Combined with Radiation Therapy in Breast Cancer: A Rapidly Evolving Landscape. Semin Radiat Oncol. 2022;32:291\u20137.","journal-title":"Semin Radiat Oncol"},{"key":"2655_CR368","doi-asserted-by":"publisher","first-page":"1477980","DOI":"10.3389\/fimmu.2024.1477980","volume":"15","author":"D Nandi","year":"2024","unstructured":"Nandi D, Sharma D. Integrating immunotherapy with conventional treatment regime for breast cancer patients- an amalgamation of armamentarium. Front Immunol. 2024;15:1477980.","journal-title":"Front Immunol"},{"key":"2655_CR369","first-page":"165265","volume":"2","author":"VP Shichkin","year":"2014","unstructured":"Shichkin VP, Moriev RM. Immunomodulatory effects of hemagglutinin- (HA-) modified A20 B-cell lymphoma expanded as a brain tumor on adoptively transferred HA-Specific CD4\u2009+\u2009T cells. Sci World J. 2014;2:165265.","journal-title":"Sci World J"},{"key":"2655_CR370","doi-asserted-by":"publisher","first-page":"3563","DOI":"10.3390\/cancers14153563","volume":"14","author":"A Aghamajidi","year":"2022","unstructured":"Aghamajidi A, Maleki Vareki S. The Effect of the Gut Microbiota on Systemic and Anti-Tumor Immunity and Response to Systemic Therapy against Cancer. Cancers (Basel). 2022;14:3563.","journal-title":"Cancers (Basel)"},{"key":"2655_CR371","doi-asserted-by":"publisher","first-page":"e100007","DOI":"10.1136\/egastro-2023-100007","volume":"1","author":"HCH Lau","year":"2023","unstructured":"Lau HCH, Zhang X, Yu J. Gut microbiota and immune alteration in cancer development: implication for immunotherapy. eGastroenterology. 2023;1:e100007.","journal-title":"eGastroenterology"},{"key":"2655_CR372","doi-asserted-by":"publisher","first-page":"1366894","DOI":"10.3389\/fimmu.2024.1366894","volume":"15","author":"VP Shichkin","year":"2024","unstructured":"Shichkin VP. Enterosorption may contribute to the reactivation of anticancer immunity and be an effective approach to tumor growth control. Front Immunol. 2024;15:1366894.","journal-title":"Front Immunol"},{"key":"2655_CR373","doi-asserted-by":"publisher","first-page":"254","DOI":"10.32471\/exp-oncology.2312-8852.vol-41-no-3.13576","volume":"41","author":"LA Sakhno","year":"2019","unstructured":"Sakhno LA, Sarnatskaya VV, Yushko LA, Snezhkova EA, Bardakhivskaya KI, Shevchuk OO, et al. Adsorptive therapy as a modificator for tumor-host interaction. Exp Oncol. 2019;41:254\u20137.","journal-title":"Exp Oncol"},{"key":"2655_CR374","doi-asserted-by":"publisher","first-page":"297","DOI":"10.15407\/oncology.2023.04.297","volume":"25","author":"KI Bardakhivska","year":"2023","unstructured":"Bardakhivska KI, Sarnatskaya VV, Gerashchenko BI, Nikolaev VG. the influence of enterosorption on system tumor and host and toxic manifestations of some chemotherapeutic agents. Oncology. 2023;25:297\u2013301.","journal-title":"Oncology"},{"key":"2655_CR375","doi-asserted-by":"publisher","first-page":"1361194","DOI":"10.3389\/fimmu.2024.1361194","volume":"15","author":"T Li","year":"2024","unstructured":"Li T, Niu M, Zhang W, Qin S, Zhou J, Yi M. CAR-NK cells for cancer immunotherapy: recent advances and future directions. Front Immunol. 2024;15:1361194.","journal-title":"Front Immunol"},{"key":"2655_CR376","doi-asserted-by":"publisher","first-page":"1454427","DOI":"10.3389\/fimmu.2024.1454427","volume":"15","author":"H Park","year":"2024","unstructured":"Park H, Kim G, Kim N, Ha S, Yim H. Efficacy and safety of natural killer cell therapy in patients with solid tumors: a systematic review and meta-analysis. Front Immunol. 2024;15:1454427.","journal-title":"Front Immunol"},{"key":"2655_CR377","doi-asserted-by":"publisher","first-page":"1574742","DOI":"10.3389\/fimmu.2025.1574742","volume":"16","author":"S Balkhi","year":"2025","unstructured":"Balkhi S, Zuccolotto G, Di Spirito A, Rosato A, Mortara L. CAR-NK cell therapy: promise and challenges in solid tumors. Front Immunol. 2025;16:1574742.","journal-title":"Front Immunol"},{"issue":"10","key":"2655_CR378","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/nrm3434","volume":"13","author":"J Massagu\u00e9","year":"2012","unstructured":"Massagu\u00e9 J. TGF\u03b2 signalling in context. Nat Rev Mol Cell Biol. 2012;13(10):616\u201330.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"10","key":"2655_CR379","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nrd3810","volume":"11","author":"RJ Akhurst","year":"2012","unstructured":"Akhurst RJ, Hata A. Targeting the TGF\u03b2 signalling pathway in disease. Nat Rev Drug Discov. 2012;11(10):790\u2013811.","journal-title":"Nat Rev Drug Discov"},{"issue":"4","key":"2655_CR380","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","volume":"50","author":"E Batlle","year":"2019","unstructured":"Batlle E, Massagu\u00e9 J. Transforming Growth Factor-\u03b2 Signaling in Immunity and Cancer. Immunity. 2019;50(4):924\u201340.","journal-title":"Immunity"},{"key":"2655_CR381","doi-asserted-by":"publisher","first-page":"1113061","DOI":"10.3389\/fmolb.2023.1113061","volume":"10","author":"P-Y Chen","year":"2023","unstructured":"Chen P-Y, Qin L, Simons M. TGF\u03b2 signaling pathways in human health and disease. Front Mol Biosci. 2023;10:1113061.","journal-title":"Front Mol Biosci"},{"issue":"1","key":"2655_CR382","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/s41467-017-02696-6","volume":"9","author":"R Ravi","year":"2018","unstructured":"Ravi R, Noonan KA, Pham V, Bedi R, Zhavoronkov A, Ozerov IV, et al. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF\u03b2 enhance the efficacy of cancer immunotherapy. Nat Commun. 2018;9(1):741.","journal-title":"Nat Commun"},{"issue":"7","key":"2655_CR383","doi-asserted-by":"publisher","first-page":"3507","DOI":"10.7150\/thno.126517","volume":"16","author":"Z Li","year":"2026","unstructured":"Li Z, Ji X, Cong X, Gao Y, Gao J. Recent advances in nanoparticles targeting TGF-\u03b2 signaling for cancer treatment. Theranostics. 2026;16(7):3507\u201340.","journal-title":"Theranostics"},{"key":"2655_CR384","doi-asserted-by":"crossref","unstructured":"Strauss J, Gatti-Mays ME, Cho BC, Hill A, Salas S, McClay E, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with human papillomavirus-associated malignancies. J Immunother Cancer. 2020;8(2):e001395.","DOI":"10.1136\/jitc-2020-001395"},{"key":"2655_CR385","doi-asserted-by":"crossref","unstructured":"Yi M, Wu Y, Niu M, Zhu S, Zhang J, Yan Y, et al. Anti-TGF-\u03b2\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer. J Immunother Cancer. 2022;10(12):e005543.","DOI":"10.1136\/jitc-2022-005543"},{"key":"2655_CR386","first-page":"433","volume":"14","author":"AH Wu","year":"2022","unstructured":"Wu AH, Vigen C, Tseng C, Garcia AA, Spicer D. Effect of chemotherapy on the gut microbiome of breast cancer patients during the first year of treatment. Breast Cancer (Dove Med Press). 2022;14:433\u201351.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"9","key":"2655_CR387","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41571-025-01052-8","volume":"22","author":"J Chen","year":"2025","unstructured":"Chen J, Deutsch E, Kroemer G, Galluzzi L, Zitvogel L. The microbiota in radiotherapy-induced cancer immunosurveillance. Nat Rev Clin Oncol. 2025;22(9):667\u201379.","journal-title":"Nat Rev Clin Oncol"},{"issue":"591","key":"2655_CR388","doi-asserted-by":"publisher","first-page":"eabe7378","DOI":"10.1126\/scitranslmed.abe7378","volume":"13","author":"JH Choe","year":"2021","unstructured":"Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Sci Transl Med. 2021;13(591):eabe7378.","journal-title":"Sci Transl Med"},{"key":"2655_CR389","doi-asserted-by":"publisher","first-page":"1662238","DOI":"10.3389\/fimmu.2025.1662238","volume":"16","author":"R Rane","year":"2025","unstructured":"Rane R, Li F, Williams A, Jayadev A, Tran NL, Winkles JA, et al. Chimeric switch and inverted cytokine receptors in T cell therapy: reprogramming T cells to overcome immune suppression in the solid tumor microenvironment. Front Immunol. 2025;16:1662238.","journal-title":"Front Immunol"},{"issue":"10","key":"2655_CR390","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.cell.2025.02.035","volume":"188","author":"L Liu","year":"2025","unstructured":"Liu L, He P, Wang Y, Ma F, Li D, Bai Z, et al. Engineering sonogenetic EchoBack-CAR T cells. Cell. 2025;188(10):2621\u2013e263620.","journal-title":"Cell"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02655-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02655-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02655-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T11:02:51Z","timestamp":1781089371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02655-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,25]]},"references-count":390,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2655"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02655-0","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,25]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}